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CHAPTER 1 INTRODUCTION
Cancer
Cancer is a disease characterized by the growth of abnormal cells that divide uncontrollably
and have the capability to penetrate and destroy normal body tissue [1]. The growth of any cancer
is a multistep process. Normal cells gradually turn into malignant cells by acquiring cancer
capabilities such as uncontrolled cell proliferation, resisting cell death (apoptosis), and activating
invasion and metastasis after somatic mutation [2].
Cancer remains the second leading cause of death in the United States, surpassed only by
heart disease, and accounts for nearly one of every four deaths [3]. Approximately 14.5 million
Americans were diagnosed with cancer as of January 1, 2014,. About 1,685,210 new cancer cases
are estimated to be diagnosed in 2016, and nearly 595,690 Americans are projected to die from
cancer in 2016, a mortality rate of about 1,630 fatalities per day [3].
Many external factors raise the risk of cancer, such as exposure to radiation, environmental
pollutants, certain infections, tobacco use, certain dietary factors, obesity, and lack of physical
activity. These factors can either directly influence genes or combine with existing genetic errors
within the cells to form mutations [4]. Mutations in cancer cells lead in developing main traits
("hallmarks") that Weinberg et al. [5] highlighted. The main traits or “hallmarks" of cancer cells
are [5]: (1) self-sufficiency in growth signals; (2) insensitivity to anti-growth signals; (3) evading
apoptosis; (4) limitless replicative potential (5) sustained angiogenesis; and (6) tissue invasion and
metastasis.
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Figure 1.1: The Six Hallmarks of Cancer, As Published In 2013 By Weinberg and Hanahan.
Cancer etiology
Carcinogenesis process can be divided theoretically into four steps [6]: initiation,
promotion, progression, and metastasis. Initiation is the first step in the process of carcinogenesis;
it involves the alteration, change, or mutation of chromosomes arising spontaneously or induced
by exposure to a carcinogenic agent. Each cell can repair the mutations before passing into new
cells [7]. However, under certain situations, cells lose their ability to fix the mutations. As the
mutations build up over time, the damaged cell is more likely to become cancerous [8]. Those
mutations can result in dysregulation of biochemical signaling pathways associated with cellular
proliferation, survival, and differentiation [6].
Promotion is the phase between a premalignant lesion and the development of invasive
cancer [7]. This step is a lengthy, reversible process. Additional and recurrent damage needs to
happen before cancer progresses. Agents, such as hormones or some drugs, cause this further
damage and are known as promoters [8]. This Promoter speeds up the pace of cell division process
and creates more genetic mutations.
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Progression is the final development of invasive cancer where genetic and phenotypic
changes and cell proliferation arise in the cells [7]. This implicates a rapid increase in the tumor
size, where cells may undergo further mutations with invasive and metastatic potential. The
production of tumor cells, known as tumorigenesis, is a process by which mutated cells receive
constant signals that command them to divide at initial proliferation cycles; abnormal cells form a
cluster in a single mass commonly known as a tumor (or neoplasm).Body conditions like genetic
factors, hormones, etc. have an effect on the progression of cancer[6].
As cancer cells proliferate, at late proliferation cycles, tumor cells acquire the ability to
invade surrounding tissue for energy and nutrients; these invaders, termed malignant cells, enter
the bloodstream or lymphatic vessels [7] by destroying basal membranes and forming secondary
tumors at distant locations in the body [8] by a process known as metastasis.
Signal transduction process in cancer
Signal transduction pathways convert environmental stimuli to changes in cell behavior
and are thus central to the control of all biological processes [9]. Most human cancers have aberrant
signal transduction elements in their development process. It is the communication processes of
cells that usually involve a cascade of protein phosphorylation events, ultimately resulting in the
activation (or inactivation) of transcriptional regulators and changes in target genes controlling cell
processes of growth, differentiation, and survival. Abnormalities in signal transduction elements
can lead to increased proliferative potential, raised invasion and metastasis, and apoptosis
inhibition [10].
Cells are regularly opened to a variety of exterior signals, ranging from soluble endocrine
and paracrine factors to signaling molecules in neighboring cells [11]. The cell-surface receptor is
the environmental signal receiver most often located on the cell surface and interacts with internal

3

4

cellular components [10]. After receiving information at the receptor, the information is converted
into other chemical forms. Changes in the concentration of chemical forms, called second
messengers, create the next step in the molecular information network. Particularly important
second messengers include cyclic AMP, cyclic GMP, calcium ion, inositol 1,4,5-trisphosphate,
(IP3), and diacylglycerol (DAG). Many second messengers elicit responses by activating protein
kinases [10]. The protein kinases transfer phosphoryl groups from ATP to specific serine,
threonine, and tyrosine residues in cytoplasmic proteins. These cytoplasmic proteins either
activate transcription factors or proteins that activate transcription factors [12]. Transcription
factors are small proteins which regulate the expression of genes within the cell, and they
ultimately change the regulation of its target gene expression [13]. In normal cell processes,
transcription factors function as a single protein or as part of a complex in the regulatory region of
the gene [13]. Some of the transcription factors have been identified as oncogenic, meaning they
regulate the function of cancer genes AP-1, NF-κB, and STAT3. Most of the transcription factors
maintain genes in an “on” position in cancer cells whereas shutting off these genes by inactivation
of transcription factors will result in cancer cell death[13]. Sometimes cell-surface receptors also
directly activate transcription factors or target genes without activating protein kinases. They can
send a signal into the nucleus and alter the transcription pattern of the cells. Thus, it is extremely
important that the cell accurately interprets these extracellular signals via Signal transduction
pathways to create the appropriate developmental or proliferative-related gene responses [14].
Genes in cancer
Mutations in the cellular genome are considered to be one of the leading causes of the
carcinogenesis process by expressing or controlling cell growth [15]. Accumulation of mutations
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in somatic genome results in increasing the risk of cancer development in humans. Based on their
functions, genes that contribute to the expansion of cancer fall into two broad categories:
(1) An oncogene is a modified gene or a group of nucleotides that encodes for proteins, increasing
the malignancy of tumor cells. A proto-oncogene is an original form of a gene that can convert
into an oncogene either after mutation or improved expression [16]. Proto-oncogenes provide
information for proteins often involved in carcinogenic signal transduction pathways, generally in
cell differentiation and cell growth regulation. Upon activation, it (or its product) develops a tumor
inducing agent, known as an oncogene. RAS, WNT, MYC, ERK, and TRK are some of the protooncogenes that may become oncogenes after activation [16].
(2)Tumor suppressor genes are the second category of cancer genes that prevent and inhibit the
development of tumors by regulating the growth of cells [17]. Following a modification or
inactivation due to a mutation, they lose the ability to make the protein that regulates cell growth,
resulting in uncontrolled cell division which develops into cancer. Some suppressor genes slow
down or stop cell proliferation, inducing apoptosis, whereas other suppressor genes are responsible
for repairing damages. Retinoblastoma susceptibility gene (RB), Wilms' tumors (WT1) and P53
are some examples for common tumor suppressor genes [17].
Lung cancer
Lung

cancer

is

a

malignant

lung

tumor characterized

by

uncontrolled cell

growth in tissues of the lung. It is currently the second leading cause of cancer death in both men
and women in the U.S in 2016. An estimated 224,390 new cases of lung cancer are expected in
2016, accounting for about 14% of all cancer diagnoses in the United States. Of the estimated
158,080 deaths estimated for 2016, cancer will account for approximately 25% of those fatalities
[3]. From 2008 to 2012, death rates from cancer were reduced by 2.9% per year in men and by
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1.9% per year in women. The 5-year average survival rates for lung cancer is 17% and Only 16%
of lung cancers are diagnosed at a localized stage, for which the 5-year survival is 55% [3].
Lung cancers are classified into three types: non-small cell lung cancers (NSCLC), small
cell lung cancers (SCLC) and lung carcinoid tumors. The classification is based on the microscopic
appearance of the tumor cells, treatment options, and growth.
Non-small cell lung cancer
Non-small cell lung cancer (NSCLC) is manifested as aggressive tumors arising from the
airway epithelial cells (majority) and interior parts of the lungs [18]. It is the most common type
of lung cancer, comprising 85% of all lung cancers. The current therapeutic options for NSCLC,
which include surgery, radiotherapy, and chemotherapy [18], have slightly improved NSCLC
survival rate at some developmental stages in both men and women. In the last 30 years, these
therapies have resulted in the plateauing of the overall five-year survival rate, which has remained
between 12-18% from 1975 -2011 [19]. Further, the five-year survival rate of patients diagnosed
with early stage NSCLC is 50%, but the rate is significantly reduced to less than 5% in patients
diagnosed with distant metastasis [20]. Despite such a wide 5-year survival rate ranging from 5%
-50%, NSCLC remains the leading cause of global cancer death [20]. Also, several studies report
that there is a high probability of reoccurrence and development of resistance to drug therapies in
NSCLC after treatment with chemotherapeutic agents [21]. Plateauing of the overall five-year
survival rate along with a high probability of reoccurrence and development of resistance to drug
therapies warrants efforts to identify novel therapeutic agents and targets for preventing and
treating NSCLC.
Non-small cell lung cancer is further divided into three groups: adenocarcinoma, squamous
cell carcinoma and large cell carcinoma. Adenocarcinoma arises from epithelial tissue which has
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a glandular origin, glandular characteristics, or both. It is the most common form of lung cancer in
people. Nearly 40% of all lung cancers in the U.S. are adenocarcinomas that originated from
peripheral lung tissues. Inhalation of cigarette smoke causes peripheral lesions, which are usually
adenocarcinomas of the lung [22]. These types of cancer grow more slowly and form smaller
masses than the other subtypes. However, they tend to form metastases at an early stage.
Squamous cell carcinoma arises in cells that line the central airways of the lungs. It accounts for
about 15% of all lung cancer cases. This type of cancer is the most aggressive and grows rapidly
in the lungs. Large cell carcinoma grows and spreads more quickly making it difficult to treat. It
accounts only for about 10% to 15% of all lung cancers.
Other types of lung cancer
Small cell lung cancer makes up about 10%-15% of all lung cancers. This type of lung
cancer tends to spread quickly. Less than 5% of lung cancers are lung carcinoid tumors, also called
lung neuroendocrine tumors. Most of these tumors develop slowly and rarely spread.
Mechanistic aberrations in lung cancer
It is becoming more accepted now that the identification of genomic alterations in lung
cancer can impact therapeutics, especially when the alterations represent “oncogenic drivers” in
the processes of tumorigenesis and progression. Mutations in oncogenic drivers, namely epidermal
growth factor receptor (EGFR), KRAS, and anaplastic lymphoma kinase (ALK) are mutually
exclusive in patients with NSCLC. However, more than 35% of mutations in oncogenic drivers of
NSCLC are still unknown. Aberrant Notch-1 and mTOR expressions are considered as emerging
oncogenic drivers in the pathobiology of NSCLC. The mutations in oncogenic drivers of NSCLC
activates the genes, transcription factors and/or miRNA that is controlling cell proliferation,
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metastasis or inducing apoptosis. Therefore, targeting for these mutations and tailoring therapy
accordingly is widely accepted.
Notch signaling pathway
Most of the signaling pathways controlling cell growth and differentiation, including
Notch, are commonly altered in cancer. Notch signaling plays a major role in the communication
process of controlling cell proliferation, differentiation, and apoptosis in cells. Notch is one of the
signaling pathways whose dysregulation has been found to contribute to many types of human
cancers [23] including of NSCLC patients [24, 25]. It shows both tumor promotion and inhibition
function in lung cancer by inducing different anti-cancer activities, namely cell proliferation,
apoptosis, and invasion. For instance, Notch-1 shows a growth-promoting function on NSCLC,
whereas in SCLC it plays a tumor-suppressive role [26]. Baumgart et al. 2010 [27] reported that
Notch-1 expression from excessive ADAM17 activities leads to subsequent regulation of the
EGFR expression and tumorigenicity of NSCLC cells. Overexpression of Notch-1 also has been
reported to inhibit apoptosis in lung adenocarcinoma [28]. Inhibiting Notch signaling by Gamma
secretase inhibitors (GSI) also prompted with apoptosis in lung squamous cell carcinoma cells
[29].
Four Notch receptors (Notch 1, 2, 3 and 4) and five ligands, including delta-like ligand
(DLL) 1, 3, and 4, and Jagged (JAG) 1 and 2 in mammals, have been identified [30]. The Notch
transmembrane receptors and their ligands play a vital role in cancer development [30]. Once a
ligand binds to the receptor, two proteolytic enzymes, namely ADAM metalloprotease and a γsecretase complex, make two proteolytic cleavages. Then it releases to the Notch intracellular
domain (NICD) [31]. The activated form of Notch, NICD, translocate to the nucleus and binds to
the transcriptional repressor to induce transcription of Notch target downstream genes such as
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the Hes family, Hey family, NF-kB, VEGF, BcL family, c-myc, and cyclin D1[32, 33]. These
Notch target downstream genes are involved in various cellular and developmental contexts [33].
Also, Notch-1 supports invasion and metastasis via regulating MMP9 expression. The elevated
expression of MMP9 induced by Notch ligand namely delta-like 1 homolog (DLK1) could be
significantly decreased by inhibiting Notch signaling using notch inhibitor namely gamma
secretase inhibitors (GSI) [34].
Notch-1 has been reported to cross-talk with NF-κB , which plays a major role in many
physiological processes [35-37]. Constitutive levels of Notch activity are vital in maintaining NFκB activity in various cell types [38]. Reduced level of Notch expressions in mice have shown to
significantly lower NF-κB activity [38]. Additionally, the downregulation of the Notch pathway
was associated with miR expression. For example, up-regulation of miR-34a inhibits NSCLC cell
proliferation, induces apoptosis and inhibits the invasion in NSCLC [39]. These results suggest
that the modification of Notch signaling may be a potential therapeutic utility in treating NSCLC.
MMP9 and uPA
Matrix metallopeptidase 9 (MMP-9), is a matrix, a class of enzymes that belong to
the zinc-metalloproteinases family. MMP-9 has a metastasis-promoting role [40, 41] and it has
been shown to be involved in degradation of the extracellular matrix and promotion of tumor
growth and metastasis by its angiogenic properties namely cell migration, aggregation, adhesion
and invasion in cancer [41-43]. MMP-9 expression increases with tumor size and its expression is
significantly higher in NSCLC cases with metastasis as compared to those without metastasis.
uPA is a serine protease which converts inactive plasminogen to active plasmin. The active
plasmin is responsible for the activation of MMP-9 which degrades extracellular matrix (ECM),
allowing cell invasion. uPA was also found to be involved in cell adhesion and migration.
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Together, MMP-9 and uPA play a major role in tumor invasion and the metastasis process.
Therefore, modulating uPA and MMP-9 could be an excellent therapy for preventing cell invasion
and metastasis in NSCLC.
NF-κB (Nuclear factor kappa-light-chain-enhancer of activated B cells)
NF-κB is one of nuclear transcription factors responsible for regulating expression of genes
involved in apoptosis, replication, tumorigenesis, inflammation, and many other physiological
processes [44]. Five NF-κB family proteins bound to IκB family proteins have been identified in
mammalian species. The IκB family proteins prevent translocation of NF-κB: IκB complex into
the nucleus. After external stimuli, NF-κB: IκB complex undergoes a phosphorylation process and
divides the NF-κB: IκB complex into individual IkB and NF-κB complexes. Individual IκBs are
recognized by the ubiquitin ligase enzyme and degraded at the IkB kinase enzyme complex.
Activated NF-κB then translocates to the nucleus and binds with different DNA-binding domains
of specific genes that are responsible for physiological responses such as an inflammatory or
immune response, a cell survival response, or cellular proliferation [44].
Constitutive activation of NF-κB is attributed to the carcinogenic function in mammalian
species as NF-κB play a key role in controlling genes in cell proliferation, cell survival [45] and
apoptosis. Some of the NF-κB transcription factors target anti-apoptotic genes, include
TRAF1, TRAF2, and BCL-2[46]. A variety of solid tumors, including prostate, breast, cervical,
pancreatic and lung cancer has shown to activate NF-kappaB expression constitutively [44, 47].
Lung cancer patients also showed high levels of NF-kappaB activation in both small cell lung
cancer (SCLC) and non-small cell lung cancer (NSCLC) [44, 47]. Elevated levels of NF-κB are
significantly associated with poor prognosis in lung cancer patients, whereas inhibition of NFkappaB using siRNA, IKK inhibitors, and IkappaB tumor suppressor showed high survival rate
10

11

and low proliferation rate [48, 49]. Thus, lowering NF-κB activity in cancer cells could be potential
molecular targets for lung cancer treatments.
MicroRNA-mediated regulation of lung cancer
MicroRNAs (miRNAs) are small, non-coding regions in RNAs (usually 20–22
nucleotides) that play a significant role in controlling basic biological functions, including
mammalian. The mechanism for miRNAs-mediated gene regulations functions by either straight
cleavage of a targeted mRNA or interfering with translation by interacting with the 3’ untranslated
region (UTR) of a target mRNA.
Usually, miRNAs have multiple target genes. Therefore, a single miRNA can often affect
multiple cellular processes including tumorigenesis [50]. Some of the microarray-based analyses
of miRNA expression studies have identified many lung cancer-associated miRNAs [51]. Aberrant
expression of miRNAs has been found to show a significant role in cancer as either oncogenes or
tumor suppressor genes [52].
miRNAs that exhibit tumor suppressing function are frequently underexpressed in lung
tumors, particularly NSCLC, compared to normal lungs, and their reduced expression has also
been associated with poor prognosis [53]. MiR-29a/b/c, miR-34a/b/c, miR-16, and miR-126 [51]
are examples for tumor suppression miRNAs. Oncogenic miRNAs are usually over-expressed in
lung cancer and the miR-17-92, a cluster of seven miRNAs, miR-21, miR-93, miR-98, miR-197,
miR-221/222, and miR-155 are reported to be involved in oncogenic miRNA in lung cancer [53].
Recent evidence shows a strong link between miRNAs and invasion and metastasis.
Several miRNAs have been found to regulate key regulators of EMT, a process central to cancer
metastasis [53]. These include miR-10b (through inhibition of HOXD10), miR-126, and the
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miRNA-200 family (which inhibit EMT inducers ZEB1 and ZEB2[53]. Therefore, manipulation
of miRNAs may be a possible therapeutic target in cancer treatment for NSCLC.
mTOR Pathway
The mechanistic target of rapamycin (mTOR) is a key regulator of cell growth and activator
of protein translation in response to amino acid abundance and growth factor signaling [54]. It
senses and integrates various nutritional and environmental cues into the cells via external stimuli.
Aberrant mTOR signaling is involved in many diseases including cancer, cardiovascular disease,
and diabetes.
The two functionally distinct protein complexes, namely mTOR complex 1, and the mTOR
complex, are key compasses in mTOR [55]. The mTORC1 is made with an mTOR-raptor,
mLST8, and two negative regulators, PRAS40 and DEPTOR [56]. The basic function of Raptor
is to regulate mTOR activity and functions by recruiting mTORC1 substrates [56]. Activated
mTORC1 from external stimuli phosphorylates two main downstream effectors, S6K1 and
4EBP1[57-59]. The targets of S6K1 include ribosomal proteins, elongation factors, and insulin
growth factor 2 [60] whereas 4EBP1 inhibits the protein translation by binding and inactivating
eIF4E (eukaryotic translation initiation factor 4E)[61]. S6K1 and 4EBP1 are used to evaluate
mTORC1 activity in vivo as they have been shown to be directly regulated by mTOR in several
studies.
Cumulative evidence shows that the lysosome at the core of mTOR complex 1 (mTORC1)
activated by EAA and glutamine via two parallel pathways, Rag GTPase-Regulator and Vps34phospholipase D1 (PLD1). For instance, knockdown of glutamine transporter SLC1A5 in cells
altered glutamine uptake and export, EAA uptake and mTORC1 activation. In vitro treatment of
cancer cells with L-γ-glutamyl-p-nitroanilide (GPNA; an inhibitor of SLC1A5) or with 2-
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aminobicyclo-(2,2,1)heptane carboxylic acid (BCH; an inhibitor of SLC7A5–SLC3A2) inhibits
glutamine-dependent activation of mTORC1 and induce autophagy [62] suggesting that glutamine
uptake and export is required for EAA activation of mTORC1. Therefore, controlling EAA uptake
and mTORC1 activation could be an excellent therapy for preventing NSCLC.
Cancer, nutrients, and phytochemicals
Deeper understanding of the pathobiology of NSCLC has led to the discovery of novel
small molecules that target genetic mutations known to play critical roles in the progression to
metastatic disease. Nutraceuticals, plant-based small molecules, contributed to drug discovery and
development processes in cancer over the last four decades[63, 64]. Plant-based small molecules
show minimum cytotoxicity and simultaneously target multiple signaling pathways involved in
cell growth, apoptosis, invasion, angiogenesis and metastasis in cancer cells [65, 66].Recent
studies on humans and animals also confirmed that phytochemicals found in the diet suppress the
inflammatory processes which would otherwise lead to transformation and initiation of
carcinogenesis. The anti-cancer function of curcumin (turmeric), resveratrol (red grapes), lycopene
(tomato), catechins (green tea), vitamin C (citrus fruits), Beta-carotene (carrot), indole 3-carbinol,
tea polyphenols, isothiocyanates and coenzyme Q10 have been confirmed in several studies. Since
cancer is the outcome of a dysregulation of multiple signaling pathways, and natural products
provoke multi-targeted activities, natural products hold great potential for treatment of human
tumors given they are specific to multiple therapeutic targets [67].
Vitamin E
Vitamin E is a fat-soluble vitamin with two major isomers: tocopherols (α-, β-, γ-, δ-) and
tocotrienols (α-, β-, γ-, δ-). Vitamin E acts as a potent antioxidant, capable of neutralizing free
radicals directly by donating hydrogen from its chromanol ring. It has also been identified to have
13
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a role in the prevention and inhibition of cancer [68, 69]. The anti-cancer properties of vitamin E,
attributed from either a combination or individual isomers, have been demonstrated in colon, lung,
prostate, and breast cancer [70, 71]. Apart from antioxidant and anti-cancer properties, Vitamin E
plays a role in protecting bone, cardiovascular, eye, nephrological and neurological diseases. The
sources of Vitamin E includes vegetable oils, including rice bran oil and palm oil, wheat germ,
barley, anatto, and certain other types of seeds, nuts, grains [72].
Heath benefits in tocotrienols
Tocotrienols were first identified in 1964 [77]. Despite its discovery in 1964, it was not
until the 1980s that tocotrienols emerged in the spotlight prior to research interest in tocopherol;
tocopherols were regarded as the major isoform with the most potent antioxidant and biological
activity [79, 80]. The unsaturated side chain of tocotrienol permits for more efficient diffusion into
tissues that have saturated fatty layers such as the brain and liver [15]. Experimental research
examining the antioxidant, free radical scavenging, effects of tocopherol and tocotrienols have
found that tocotrienols appear superior due to their better distribution in the lipid layers of the cell
membrane [80] [16]. Cumulative evidence from recent investigations have shown that tocotrienols
may be superior to tocopherols in their anti-cholesterolemic (unique to tocotrienols only),
antioxidant, anti-cancer, anti-inflammatory, cardioprotective and neuroprotective properties [77].
Additional pharmacological potential of tocotrienols has also been summarized in Table 1. Table
01 has been adapted from [81], modified, and used in this thesis.
Table 01: Biological properties of tocotrienols
Protective activity

Tocotrienol type

Proposed mechanism of action

Anti-diabetic

TRF from palm oil and
rice bran oil

Prevents the formation of advanced
glycation endproducts in diabetic rats
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Protective activity

Antiinflammatory

Antioxidant

Tocotrienol type

Proposed mechanism of action

α-T, γ-T, δ-T

Reduces hyperglycemia and hyperlipidemia
in diabetic rats

α-T, γ-T, δ-T

Inhibition of NF-κB signaling pathway

α-T, γ-T, δ-T

Inhibition of oxidative-nitrosative stress

α-T, γ-T, δ-T

Inhibition of TNF-α, IL-1β, TGF-β1 and
caspase-3 activity

TRF from palm and rice
oil

Reduction of glucose-insulin index

α-T, γ-T, δ-T

Increase in insulin sensitivity

α-T, γ-T, δ-T

Suppression of NF-κB, TNF-α, IL-1, IL-6,
IL-8 and iNOS

α-T, γ-T, δ-T

Suppression of cyclooxygenase-2 activity

α-T, γ-T, δ-T

Suppression of STAT-3 signaling pathway

α-T, γ-T, δ-T

Increase in the activity of antioxidant
enzymes

Quenching and scavenging of free radicals
TRF from palm oil and
rice bran oil, α-T, γ-T, δ-T

Immunostimulatory

Cardio-protective

α-T, γ-T, δ-T

Inhibition of lipid peroxidation

α-T, δ-T

Induction of antibody production

α-T, γ-T, δ-T

Induction of IFN-γ, IL-4, IL-1β production

δ-T

Suppression of TNF-α

α-T, γ-T

Inhibition of HMG-CoA reductase activity
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Protective activity

Neuro-protective

Hepato-protective

Nephroprotective

Tocotrienol type

Proposed mechanism of action

α-T, γ-T

Inhibition of expression of cell adhesion
molecules

α-T, γ-T

Reduction in the levels of blood cholesterol

TRF from palm oil and
rice bran oil, δ-T

Inhibition of lipid peroxidation

γ-T, δ-T

Downregulation of c-Src expression

γ-T, δ-T

Upregulation of phosphorylation of Akt

TRF from palm oil

Reduction in the production of
apolipoprotein B, platelet derived factor-4,
thromboxane B2

TRF from palm oil and
rice bran oil

Downregulation of TGF-β

α-T

Inhibition of PP 60 (c-Src) kinase activity
and phosphorylation of Erk

α-T, γ-T

Inhibition of 12-lipoxygenase activity

α-T, γ-T, δ-T

Reduction of oxidative stress

α-T, γ-T

Inhibition of lipid peroxidation and
oxidative damage

γT, δT

Induction of the expression of CYP450,
UGT1A1 and MDR-protein 1

TRF from palm oil and
rice bran oil, αT, γT, δT

Induction of hepatic antioxidant status

TRF from rice bran oil, α- Inhibition of oxidative-nitrosative stress
T, γT
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Protective activity

Tocotrienol type

Proposed mechanism of action

TRF from palm oil and
rice bran oil, αT, γT

Downregulating the expression of NF-κB,
TGF-β, TNF-α and caspase-3

Tocotrienols and cancer
In addition to above properties, tocotrienols display anti-cancer properties via antiproliferative, anti-survival, pro-apoptotic, antiangiogenic, and anti-inflammatory activities in invitro and in-vivo studies. Several cell culture studies have demonstrated the ability of tocotrienols
to inhibit cancerous cell growth/proliferation of breast, prostate, lung, bladder, liver, colorectal,
and pancreas origin [70, 73]. In an animal study, mice treated with tocotrienols showed significant
tumor suppression as monotherapy [73] or in combination with chemotherapeutic agents [74].
Tocotrienols inhibited metastatic B16 melanoma in female mice, and δT was more active than γT
in this study [70]. In another study, γT and δT also delayed tumor growth in mice implanted with
hepatoma [70]. Further cumulative evidence has reported that tocotrienol isomers individually or
in combinations exhibit anticancer properties by inducing apoptosis [75-77]. For instance,
apoptosis induced by tocotrienols involves mitochondrial depolarization [78] and is facilitated via
the increased expression of Bax [79-81], cleavage of Bid [80], the release of cytochrome C [82],
and activation of caspase-9, which in turn leads to activation of caspase-3 [82, 83].
Anti-invasive effects of δT in cancer cells have been reported in several studies. Yap et al.
[17] used a Matrigel invasion assay to show that δT have the ability to halt the invasion of prostate
cancer cells [84]. In another study, a 2-fold suppression on cell invasion using annatto extracted
from δ-tocotrienols was observed at a concentration ranging from 20 to 30 µM in non-small cell
lung carcinoma (NSCLC) [85]. Combinational treatment of cisplatin and δ-tocotrienol has also
been found to effectively reduce the invasive capability of NSCLC cells in comparison to either
17
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agent alone [85]. The inhibition of angiogenesis by tocotrienols is observed by inhibition of VEGF
expression [86] and VEGF receptor signaling [76] in some studies. All these studies suggest that
tocotrienols have the potential to both prevent and treat cancer.
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CHAPTER 2 SPECIFIC OBJECTIVES
NSCLC is one of the leading causes of death among cancers in the USA. The current main
therapies for lung cancer are surgery, chemotherapy, radiation and molecular-targeted or combined
modalities. Despite these treatments, the five-year survival rate has not changed over the last four
decades. This plateauing five-year survival could be attributed to late diagnosis, tumor metastasis,
chemo/radioresistance, and tumor recurrence. Poor outcomes suggest that it is important to identify
newer and novel therapeutic agents for improving treatments and survival rates for NSCLC
patients.
All cancers, including NSCLC, show aberrant cellular signaling pathways that are required
for the complex communication networks between the interior and exterior of cells. Cellular
signaling pathways transmit basic information to regulate diverse processes, such as protein
synthesis, cell growth, cell architecture, migration, differentiation, and programmed cell death.
Understanding these cellular signaling pathways and how they differ in cancer will help to identify
the novel therapeutic target. Notch signaling pathways have been designated as one of functional
signaling pathways in the normal development of many tissues and cell types, through diverse
effects on differentiation, proliferation, and survival. The up-regulated Notch expression has been
observed in many types of cancers including NSCLC patients. Notch-1 has shown cross-talk with
nuclear factor NF-κB in different studies and indicates that it plays a major role in many
physiological processes, such as cell proliferation, cell death, inflammation, apoptosis and immune
response in cancers. MMP-9 is a metalloprotein downstream to Notch-1 and NF-κB that regulates
cell migration, angiogenesis, adhesion, aggregation and immune response in cancer.

The

urokinase-type plasminogen activator (uPA) pathway is one of the major pathways that is involved
in modulating MMP-9 activities. Down-regulation of Notch-1 has shown anti-invasive effects on
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some cancer cells by inhibiting NF-κb and matrix metalloproteinase-9. Therefore, modulating uPA
and/or MMP-9, along with NF-κb, Notch -1 and miR451, from a single compound could be an
excellent therapy for preventing cell invasion and metastasis in NSCLC. The first specific aim of
this study is proposed to investigate the effect of δT on the NSCLC cell line with the working
hypothesis that the MMP-9 dependent invasion and metastasis of non-small cell lung cancer
(NSCLC) cell would be inhibited by suppressing Notch-1 mediated NF-κb and uPA pathways.
Studying the metabolome of NSCLC is a potentially informative mirror of the signaling
and biochemical dynamics which is strongly geared toward the discovery of new biomarkers of
disease onset, progression and effects of treatment regimes. Although anti-cancer effects of δT
were investigated using molecular biology techniques, in our previous studies and in specific aim
one, the change in the metabolomics patterns produced due to the introduction of δT in non-small
cell lung carcinoma cell lines has not been investigated yet. Further, the primary energy source of
NSCLC is glutamine, and this cancer exhibits a high rate of glutamine dependency during its
growth and development. Glutamine and essential amino acids (EAA) in NSCLC are reported to
upregulate mTOR, a bioenergetics sensor which regulates cell growth, cell survival, and protein
synthesis. SLC1A5/SLC7A5 transporters that allow glutamine and EAA to enter the proliferating
tumors and send a regulatory signal to mTOR are novel concepts in cancer cell growth and
development. Therefore, inhibiting glutamine uptake via blocking or downregulating glutamine
transporters would be an excellent therapeutic target for NSCLC treatment. Therefore, the second
specific aim is proposed to study the effect of δT on the metabolite dysregulation of glutamine and
its derivatives in NSCLS using 1H-NMR based metabolomics, with expression of NSCLC cell
growth, development, glutamine transporters and mTOR pathway.
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Our previous studies showed the potential of δT against NSCLC prevention via
downregulating notch-1 and other genes in cell culture studies. As a next step, we want to start a
clinical trial and investigate the effect of tocotrienol on human lung cancer patients. However, pure
δT isomer to treat cancer is not plausible since it is difficult to isolate, is expensive, and pure δT
isomers are presently not available in quantities required for animal or clinical studies. The specific
aim three is performed to investigate the anti-cancer effects of commercially available tocotrienols
isomer rich capsules on NSCLC cell lines and explore molecular mechanisms behind anti-cancer
regulations by testing the expression of Notch-1 and its downstream stream genes.
Hypothesis
The overall goal of the study is to evaluate tocotrienols as an anticancer nutraceutical. To
achieve this goal, we hypothesize that δT, acting either as a single agent or in combination with
other tocotrienol isomers, will be an effective therapeutic strategy for treating NSCLC.
SPECIFIC AIM 01
To investigate the effect of on the NSCLC cell line with the working hypothesis that
the MMP-9 dependent invasion and metastasis of non-small cell lung cancer (NSCLC)
cell is inhibited by suppressing Notch-1 mediated NF-κb and uPA pathways.
The effect of δT on cell migration, invasion, and cell adhesion and aggregation capability
was investigated using a suitable assay to investigate functional activities of MMP-9 upon the δT
intervention. MMP-9 enzyme activity with δT was also determined using gel zymography. The
various proteins, genes, and miRNA involved in the MMP-9 activation pathways namely Notch1, NF-κb and uPA, was investigated by using RT-PCR and Western blot analysis.
SPECIFIC AIM 02:
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To investigate the effect of δT on the metabolite dysregulation of glutamine and its
derivatives in NSCLS using 1H-NMR based metabolomics, with an expression of NSCLC
growth, development, glutamine transporters and mTOR pathway.
The endo-metabolome of the cells was determined using 1H-NMR Spectroscopy and
Multivariate statistical analyses methods namely Principal component analysis (PCA), PLS-DA
and OPLS-DA, was performed with SIMCA+ and MetaboAnalyst 3.0 to identify differences
among treated and non-treated NSCLC cells. By using partial least squares (PLS) regression
analysis, the correlation between the metabolomic profile and anticancer effects namely antiproliferation, apoptosis, and invasion, was performed to identify how the metabolites
mechanistically affect cell behavior. Changes in specific metabolite concentrations due to
intervention with δT was quantified by Chenomx-NMR Suite and Chenomx data further analyzed
with metboanyst 3.0 software by using different analysis methods such as pathway analysis, heat
maps, etc. The altered metabolites in cells were used to gain insight into biochemical pathways
and differences in response to tocotrienol interventions. In addition, altered metabolites identified
from Chenomx-NMR suite were further analyzed using metaboanalyst software and fitted into
appropriate pathways. Finally, impacted pathways were validated using western blot analysis.
SPECIFIC AIM 03
To investigate the effect of a commercially available tocotrienol-rich capsule directly
extracted from palm oil on growth inhibition of NSCLC cells and on induction of apoptosis
by inhibition of Notch-1 signaling via the NF-kB pathway.
MTS assay was performed to determine the δT IC50 (half inhibition concentration) on
H520 and A549 and data from MTS assay was confirmed from clonogenic (or colony forming)
assay. Induction of apoptosis in these cell lines by treating with δT was explored by using flow
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cytometry and histone ELISA. The cell invasion and migration capabilities after induction of
tocotrienol was also investigated by using wound healing and cell invasion assays. Molecular
mechanisms behind these regulations were explored by testing the expression of Notch-1 and its
downstream genes at the protein and mRNA levels from RT-PCR and western blot analysis.
Finally, NF-ĸB activity was measured by ELISA assay.
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CHAPTER 3 DELTA TOCOTRIENOL INHIBITS MMP-9 DEPENDENT INVASION
AND METASTASIS OF NON-SMALL CELL LUNG CANCER (NSCLC) CELLS.
Introduction
With current advances in the understanding of mechanisms of cancer invasion and
metastasis, it is very clear that matrix metalloproteinases (MMPs), an enzyme including 21
subtypes in humans [87], show a strong association with metastasis [87]. Several study designs
ranging from cell culture investigation[88] to clinical investigations [89] have shown inhibition of
MMPs involved in decreasing metastasis in NSCLC. Matrix metalloproteinase 9 (MMP9), a
subtype of MMPs, regulates cell migration, angiogenesis, adhesion, aggregation and immune
response in cancer [90, 91]. In this process, MMP9 is primarily responsible for degrading collagen
type IV and elastin in basal membranes, facilitating the way for lung cancer metastasis. Elevated
levels of MMP-9 also have been found in the serum of lung carcinomas patients [92].Therefore,
modulating MMP 9 protein expressions and their activities would be excellent therapeutic targets
for the inhibition of local invasion or distant metastases in NSCLC.
The urokinase-type plasminogen activator (uPA) pathway is one of the major pathways
that can directly modulate MMP-9 activities in cancer [93]. The urokinase-type plasminogen
activator (uPA) system includes serine protease, urokinase-type plasminogen activator receptor
(uPAR), and the endogenous inhibitors, plasminogen activator inhibitors 1 and 2[94]. The uPA, a
plasminogen activator, facilitates extracellular matrix degradation by converting zymogen
plasminogen into plasmin[95]. Then, plasmin facilitates the conversation of inactive pro MMP-9
into active MMP-9. Higher expression of the uPA system was reported in NSCLC tissue as
compared to normal lung tissue[96]. Rao, et al. [97] using antisense technology showed that the
inhibition of uPA and MMP-9 might be a promising anti-invasion and anti-metastatic strategy for
cancer gene therapy in lung cancer. Although inhibition of uPA and/or MMP-9 is a possible
24

25

therapeutic target for preventing local invasion or distant metastases in lung cancer, uPA, and
MMP-9 pathways have shown cross talks with external factors, namely transcription factors,
signaling pathways, and miRNA; these cross-talks have made it more complex them to modulate
directly. Tong, et al. [98]showed that nuclear factor-κb (NF-κb), a well-known transcription factor
for cancer initiation and progression, directly bonded to the uPA promoter in vitro, and that the
inhibition of NF-κB activity impaired the cell invasion and reduced the uPA production in NSCLC
cells. Recently, accumulating evidence has suggested that the NF-κb signaling pathway contributes
to the progression of metastasis by regulating MMP9 in colorectal cancer[99], prostate
cancer[100], renal cancer[101], ovarian cancer[102], and head and neck cancer [103]. However,
the role of NF-κb mediated uPA and/or MMP-9 function in cell invasion and metastasis in lung
cancer remains generally unclear.
Elevated miR-451 expression levels, an abundant class of small non-coding RNAs that
modulates gene expression in a posttranscriptional manner through sequence-specific binding to
target mRNA, were also reported to decrease cell invasion and metastasis, accompanied with the
decrease of matrix metalloproteinase-9 (MMP-9) expression levels in primary liver cancer[104].
Elevated miR-451 expressions were also found to suppress cell proliferation and metastasis in
A549 lung cancer cells lines[105]. However, the impact of miR-451 on NSCLC invasion and
metastasis has not been investigated via target MMP-9, uPA, NF-κb and Notch-1 signaling
pathway. Therefore, modulating uPA and/or MMP-9 along with NF-κb, Notch -1 and miR451,
from a single compound could be a possible therapy for preventing cell invasion and metastasis in
NSCLC.
Previous studies from our laboratory showed that δT, an isomer of vitamin E, found
naturally in palm oils, inhibit NF- кb signaling pathways via the down-regulation of Notch-1
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thereby decreasing the proliferation and at the same time inducing the apoptosis of NSCLC cells
in a dose and time-dependent manner [8, 24, 106, 107]. The present study aims to investigate the
effect of δT on the NSCLC cell line with the working hypothesis that the MMP-9 dependent
invasion and metastasis of non-small cell lung cancer (NSCLC) cell would be inhibited by
suppressing Notch-1 mediated NF-κb and uPA pathways.
Materials and methods
Reagents and antibodies.
δT was a kind gift from American River Nutrition (DeltaGold® MA, USA). DMSO, TNFα, bovine serum albumin (BSA), was purchased from Sigma-Aldrich (St. Louis, Mo., U.S.A.); the
protein assay kit was obtained from Bio-Rad Labs. (Hercules, Calif., U.S.A.). NSCLC cell lines
of human A549, H1299 were obtained from ATCC. RPMI medium (Mediatech, Manassas, VA)
used as a growth medium for cells. Antibodies namely β-actin, MMP-9, HES-1, Notch-1 (Cell
Signaling Technology, Danvers, MA) and uPA (Santa Cruz Biotechnology, USA) used for western
blot analysis.
Cell Culture and treatments.
NSCLC cell lines, namely A549 and H1299, were cultured in RPMI medium (Mediatech,
Manassas, VA) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin in
5% CO2 and 37 C 0. The culture medium was renewed every 2 to 3 days. Adherent cells were
detached by incubation with trypsin-EDTA and centrifuged at 1500 RPM. The treatment media
was prepared by mixing δT (<.01% DMSO as a vector) in the RPMI medium whereas the control
was treated only with RPMI media containing <.01% DMSO. The δT, 10μM, 20μM and 30μM
concentration containing <.01% DMSO, was chosen as the treatment concentration.
Cell viability assay.
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MTS assay was conducted to analyze the anti-proliferative effects of δT on the above
NSCLC cell lines. 5x105 of A549 and H1299 cells were seeded in a 96-well plate and incubated
overnight. After incubation, the medium was replaced, and cells were treated with fresh medium
containing < 0.10% DMSO (control) and treatment medium containing 10μM, 20μM, 30μM and
40μM of δT. After 72 hours of treatment, 20µl of CellTiter 96 Aqueous One Solution Reagent
from Promega, (Madison, WI) was added to each well and incubated for 2 hours at 37°C in a
humidified 5% CO2 atmosphere. Then the absorbance at 490nm was measured using the Bio-Tek
ELx800 plate reader (Winooski, VT). Each variant of the experiment was performed with six
replicates.
Cell invasion assay.
The ability of A549 and H1299 lung cancer cells to pass through filters coated with
Matrigel was assessed by BD Biocoat invasion kit (BD, San Jose, CA). 2.5 x 10 5 both A549 and
H1299 cells were extracted in an aqueous environment with PBS and resuspended into each upper
chamber of six well plates with a serum-free medium in the presence or absence of treatment. 3ml
of culture medium with 15 % FBS was added to each lower chamber of the six-well plate and
incubated for 20 h. After the incubation, the cells in the upper chamber were removed using a
cotton swab, and the cells invading across the Matrigel to the lower surface of the membrane were
fixed with 4% Paraformaldehyde and stained with 2% crystal violet. The invading cells on the
lower surface of the membrane filter were counted and pictured with the camera attached to the
light microscope. The data were presented as cells attached to the bottom surface from randomly
chosen fields. Each experiment was carried out in triplicate. Again, the same procedure was
continued up to 20 h incubation in a BD Biocoat invasion kit; then the cells on the upper chamber
were removed using a cotton swab, and 50uL of MTS reagent was added into the lower chamber.
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The absorbance of the media contained in the lower chamber was measured at 450nm using the
Bio-Tek ELx800 plate reader (Winooski, VT). Each experimental condition was performed in
triplicates.
Cell migration assay.
To detect the migration speed of a cells using wound healing assay, A549, and H1299 cells
were seeded in a six-well plate at the concentration of 1 X 10 6 cells per well. After the cells, had
been incubated for 36 hrs., the culture media was removed and treated with or without treatment
media. Scratches were made using a pipette tip (200μl) and photographed immediately (time 0).
After 20 h incubation, all the wound areas were washed with PBS three times to make sure that no
loosely held cells were attached. The plate was imaged, and the width of the scratch was measured
by a Nikon H 600L microscope connected to the microscope.
Cell adhesion assay.
The cell lines A549, and H1299 (one million) were pre-treated with or without different
concentrations of δT (control, 10μM, 20μM, and 30μM) for 72 hrs. The cell lines were suspended
in an RPMI medium to form a single-cell suspension and 2 x 106 cells/ml (2 x 105 cells/well) were
seeded into a 96-well microtiter cell culture plate pre-coated with Matrigel®. After 1h of
incubation at 370C, the wells were washed three times with PBS to remove non-adherent cells and
100mL of RPMI medium with 20μM MTS reagent was added into each well for an additional 2h.
As a measure of cell viability, the absorbance at 570 nm was taken on anELx800 plate reader (BioTek, Winooski, VT). Significant differences between control and treatments were evaluated using
ezANOVA.
Cell aggregation assay.
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To investigate the anti-aggregation capabilities of δT, a single cell suspension was obtained
using standard trypsinization procedure. A total of 2 x 10 5 cells in 1 ml of RPMI medium with or
without different concentrations of δT (10μM, 20μM, and 30μM) were placed in polystyrene micro
tubes and were gently shaken every 5 min for 1 hr. at 370C. At the end glutaraldehyde (at a final
concentration 2% (v/v)) was added to stop the aggregation process. Homotypic aggregation was
evaluated and photographed by a Luna automated cell counter (Logos Biosystems, USA).
Aggregates were counted per square cm, and significant differences between control and
treatments were evaluated using ezANOVA
Zymogram gel assay.
To investigate the activity of MMP-9, A549, and H1299 cells were seeded in a six-well
plate with or without treatment by δT in FBS-free RPMI media. The media of all groups was
removed and concentrated into 10X media by using 3KDa amicon centrifugal filters (EMD
Millipore, USA). Then the total protein concentrations of the concentrated media were estimated
by Pierce BSA Protein Assay kit and normalized into 2000mg into the sample. Zymogram precast
gel (Bio-Rad, Hercules, CA) with gelatin was used as a separation gel. One-part sample was mixed
with two parts of zymogram sample buffer. Samples were loaded in the gel, and the gel was run
with 1x Tris-Glycine-SDS running buffer according to the standard running conditions (100V,
constant voltage). Run time was for 90 min or when the bromophenol blue tracking dye reached
the bottom of the gel. After running, the Zymogram renaturing buffer (10x) was diluted (1:9) with
double distilled water and the gel was incubated in the buffer (100 ml for one or two mini-gels)
with gentle agitation for 30 minutes at room temperature. Later zymogram renaturing buffer was
decanted and replaced with 1x zymogram developing buffer (100 ml for one or two mini-gels).
The gel was equilibrated for 30 minutes at room temperature with gentle agitation, and then the
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buffer was replaced with fresh 1x zymogram developing buffer and again incubated at 37oC
overnight for maximum sensitivity. The gel was stained with Coomassie blue R-250 for 30 minutes
to 1 hour the next day. For maximum contrast, stain concentration of 0.5% (w/v in 40% methanol
and 10 % acetic acid) was used instead of the usual concentration of 0.1%. Gels were destained
with an appropriate coomassie R-250 destaining solution (161-0438) (Methanol: Acetic acid:
Water (40: 10: 50). Areas of protease activity appeared as clear bands against a dark blue
background where the protease had digested the substrate.
Real-time quantitative PCR
One million A549 and H520 cells were seeded in 100mm dish per plate and incubated for
24 hours. Subsequently, culturing media was replaced with treatment or control medium, incubated
for another 72 h. Then, total RNA was isolated using RNeasy Mini Kit from QIAGEN (Valencia,
CA) according to the manufacturer’s protocols. 1000ng of total RNA from each sample was
subjected to first strand cDNA synthesis using high capacity RNA to cDNA master mix (Applied
Biosystems, Foster City, CA) in a total volume of 50 ml. qRT-PCR was performed as part of gene
expression

analysis.

The

appropriate

primers

sense

of

MMP-9,

5′-

CAACATCACCTATTGGATCC-3′, antisense of MMP-9, 5′- CGGGTGTAGAGTCTCTCGCT3′ (antisense). sense of Bactin, 5′-ACCAACTGGGACGACATGGAGAAG-3′; antisense of
5′-TACGACCAGAGGCATACAGGGACT-3′ere used for PCR amplifications. Diluted cDNA (2
uL) and 2 uL of each reverse and forward primer and 12.5 uL master mix (SYBR GREEN PCR
Master Mix; Applied Biosystems, Warrington, UK) were used in each 25 uL PCR reaction
performed in Eppendorf master cycler realplex 4 (Eppendorf, Hauppauge, NY) at 25C for 10 min,
followed by 48 C0 for 30 min and 95 C0 for 5 min. Expression values were normalized with Bactin). Each gene expression was tested in triplicate.
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Western blot analysis.
To investigate the protein expression of A549 and H1299 with δT treatment, the one
million cells were seeded in 100mm dish per plate and incubated for 24hours; then the cells
incubated for 72 hours with treatment and control medium. Subsequently, the cells were lysed in
the cold 1X cell lysis buffer (Cell Signaling Technology Danvers, MA) for 30 min on ice with 1X
protease inhibitor (Cell Signaling Technology Danvers, MA). Then protein concentrations were
calculated by using Pierce BSA Protein Assay kit (Bio-Rad Laboratories, CA). Subsequently, 50
mg of total cell lysates was mixed with equal amounts of 4X lemma buffer (Bio-Rad Laboratories,
CA) and samples were loaded on 10% SDS-polyacrylamide gel electrophoresis. After
electrophoresis, the gel electrophoretically was transferred to a nitrocellulose membrane
(Whatman, Clifton, NJ) using a transfer buffer (25mM Tris, 190mM glycine, 20% methanol) in a
Hoefer TE70XP transfer apparatus (Holliston, MA). The membranes were incubated for 2 h at
room temperature with 5% BSA in 1x TBS buffer containing 0.1% Tween. After that, the
membranes were incubated overnight at 4C with primary antibodies (1: 1,000). The membranes
were washed three times with TBS-T and subsequently incubated with the secondary antibodies
(1:5,000) containing 2% BSA for 2 h at room temperature. The signal intensity was then measured
by chemiluminescent image with chemiDoc XRS (Bio-Rad Laboratories, CA).
NF-κB binding activity.
To determine the NF-κB transcription factor binding activity, A549 and H1299 were
seeded in Petri dishes and incubated for 24 hours. Cells were then treated with or without δT. After
72 hours of treatment, cells were collected and washed with the PBS. The nuclear protein
extraction was performed with NE- PER ® Nuclear and cytoplasmic extraction reagent kit (Thermo
Scientific, USA) based on the manufacturer’s protocols. Nuclear protein concentrations were
31

32

determined using the Pierce BCA protein assay kit (Rockford, IL). Then NF-κB Filter Plate Assay
Kit obtained from Signosis (Sunnyvale, CA) and used to determine the NF-κB DNA binding
ability. The assay was conducted according to the manufacturer’s protocol. Briefly, the biotinlabeled DNA sequence of NF-κB was mixed with 3µg of nuclear extract to make an NF-κB-DNA
binding complex. Then, 10µl TF binding buffer mix, 2µl NF-κB probe, 3µg and distilled water
was added to each sample and brought the total volume up to 20µl. The filter plate was used to
retain the bound NF-κB probe while the unbound NF-κB probe was filtered out. The bound, prelabeled NF-κB probe was then eluted from the filter, collected and transferred to a hybridization
plate for quantitative analysis. NF-κB probe was further detected using streptavidin-HRP, and the
luminescence of the probe was measured using an Ultra Multifunctional Microplate Reader from
Tecan (Vienna, Virginia).
miRNA 451 expression analysis.
To investigate the miRNA 451 expression of A549 and H1299, the total RNA was
extracted from the cultured cells using RNeasy Mini Kit from QIAGEN according to the
manufacturer’s protocols. The concentration and purity of the RNA were determined using
ultraviolet spectrophotometry using the Nanodrop 2000 system (Thermo, Japan). The quantitative
real-time PCR was performed using SYBR GREEN PCR Master Mix (Applied Biosystems,
Warrington,

UK)

according

to the

manufacturer's

instructions.

U-6

primers

from

miScript miRNA PCR (Valencia, CA) was used as an endogenous reference, and its levels were
used for normalization.
Results
Anti-proliferative effect of δT.
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The MTS assay showed a dose-dependent decrease in cell growth and proliferation in both
A549 and H1299 cells with addition of δT. After 72 hours of incubations with 10, 20, 30 and 40
μM of δT doses, ~ 10, 40, 80 and 85% of cell growth inhibition was observed, respectively,
compared to control in A549 cells. Similarly, the H1299 cell line showed ~ 25, 20, 55 and 87%
cell growth inhibition, respectively, with the same doses and conditions. (Figure 3.1.)
Inhibition of cell invasion and migration by δT.
We observed dose-dependent anti-invasive effects of δT in A549 and H1299 cells at the
concentration levels ranging from 0 – 30µM in Matri gel invasion assay (Figure 3.2AB). At 10,
20 and 30 µM concentrations, invasion was reduced by ~ 10%, 35% and 65% in A549 cell lines,
respectively, for 72 h incubation; similarly, H1299 cells also showed ~ 35% 45% and 70 %
inhibition of cell invasion under the same conditions. For further confirmation, microscopic
images of the migrated cell through the membrane were taken, stained and analyzed. In A549, we
observed that a low number of cells migrated through the membrane as compared with untreated
cells. Also, we hardly observed any invaded cells at 30 µM treatments in H1299 (P <0.05 at 30
µM treatment) (Figure 3.2CD). The wound healing assay was performed to investigate the
migration of A549 and H1299 after δT treatment. As showed in (Figure 3.3AB), δT significantly
inhibited the migration of cells after 20 h treatment with 30 µM δT.
Inhibition of cell aggregation and adhesion capabilities by δT.
As shown in Figure 3.4, δT inhibits cell aggregation at 30µM of δT in both A549 and
H1299 cells, respectively. To test the effects of δT on cell adhesion to the matrigel surface, A549
and H1299 cells were treated with δT for 72 h and adhesion capacities to Matrigel surface were
measured. We observed a dose-dependent inhibition of cell adhesion in both A549 and H1299
cells. (Figure 3.5.)
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δT suppressed secretion and expression of MMP-9.
Since metalloproteinase plays a crucial role in cell invasion, we then carried out the
zymography assay to compare the activity of MMPs in treated and control cells. A dose-dependent
reduction in the enzyme activity of MMP-9 was observed in zymography assay with δT (Figure
3.6) at concentrations of 0μM, 10μM, 20μM, and 30μM. TNF- α was used as a positive control.
The results of the Western blot analysis indicates that δT inhibits MMP-9 protein expressions in a
dose and time-dependent manner compared to the control group in both A549 and H1299 cells
(Figure 3.7) In order to verify whether the inhibition of MMP-9 protein expression in Western blot
analysis was the result of decreasing the m-RNA expression, real time-PCR analysis was
performed.We observed that the mRNA level of MMp-9 decreased significantly in a dosedependent manner, compared to the control group (Figure 3.8AB), in both A549 and H1299 cells,
after the treatment with δT for 72 h. The δT mediated change in the mRNA levels of MMP-9
correlated with the protein levels expression of MMP-9, as indicated by the results from the
Western blot analysis, suggesting that δT may regulate MMP-9 expression at transcription levels,
up steam gene or other factors such as miRNA.
δT inhibits expression uPA/Notch-1 pathway proteins.
To investigate the possible metastatic link between MMP-9 and uPA/Notch pathways, the
protein expression of uPA/Notch-1 pathways protein in A549 and H1299 cells treated with various
concentrations of δT were examined from western blot analysis. Based on our western blot data,
we observed the dose-dependent inhibition of uPA protein expression, in both A549 and H1299
lines tested, with δT (Figure 3.7). In addition, δT significantly inhibited the Notch-1 and its
downstream signaling molecule Hes-1 in A549 and H1299 cells, compared to Control (Figure
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3.7). The simultaneous inhibition of uPA/Notch-1 and MMp-9 with δT in protein levels suggests
a possible metastatic link between MMP-9 and uPA/Notch-1.
δT increase expression of miR-451.
To investigate the differences in miR-451 expression in A549 and H1299 cells upon
treatment by δT, we conducted a miRNA array analysis using the RT 2 miRNA PCR array system
(SABiosciences, MD). We found that miR-451 expression was 2-fold and 3.5-fold higher in the in
A549 and H1299 cells, respectively, with δT treated cells compared to control (Figure 3.8CD).
These results suggest that δT could inhibit the progression of NSCLC through induction of miR451 A549 and H1299 cells.
Inhibition of NF-κB DNA-binding activity with δT.
we investigated whether δT modulates the nuclear translocation of NF-κB and influences
the transcription of uPA/MMp9. Based on NF-kB Filter Plate Assay results, δT significantly
inhibited the DNA-binding activity of NF-κB in a dose-dependent manner for both A549 and
H1299 lines tested (Figure 3.9).
Discussion
In previous studies, we have reported that δT inhibits uncontrolled cell proliferation and
invasion and induces cell apoptosis [24, 106, 108]. Lim et al. [109] suggested that δT is the most
effective and efficient apoptotic executor compare to other tocotrienols isomers. Liu et al. [110]
showed that γ-tocotrienol inhibits cell invasion and metastasis of the human gastric system by
down-regulating MMP-9 and MMP-2. However, anti-metastasis functions of δT on lung cancer,
such as invasion, migration, adhesion, aggregation and enzyme functions, have not been
investigated to date. In this study. We demonstrated that δT decreased migration and invasion in
lung cancer cells by suppressing the Notch 1 signaling pathway, inhibiting the nuclear
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translocation and DNA binding activity of NF-κB, and reducing the level of uPA expression and
activities of MMP-9.
Based on the data, 0-30 uM of δT suppresses the cell migratory and invasive abilities of
A549 and H1299 cells at non-necrotic concentrations in this study. In our previous study, by
performing histone ELISA and ANNEXIN V stain based flow cytometry analysis, we clearly
demonstrated that the 0-30 uM range of δT was not necrotic to A549 and H1299 cells, and it
induced apoptosis in A549 and H1299 cell lines dose-dependently [24]. δT was also reported to
inhibit the proliferation of human liver cancer cell line (HepG2)[111], breast cancer[112], prostate
cancer[112, 113], human leukemia cells, murine melanoma cells and malignant epithelial
cells[112], in a dose- and time-dependent manner. We also observed a dose-dependent decrease in
cell proliferation within 0-30 uM of δT for 72 h in MTS assay in this study. Therefore, 0-30 uM
of δT for 72hrs appears to be sufficiently efficacious enough to exert apoptotic effects in lung
cancer cell lines and decrease proliferation, which could lead to a decrease in invasion and
migration of lung cancer cells.
The metastasis process starts from local invasion to distant metastasis and involves
multiple distinct steps: migration/invasion through the ECM/basement membrane and entry into
the circulatory system; survival without contact with the ECM; adhesion to the wall of lymphatic
or blood vessels, and exit from the vessels (extravasation); and survival and proliferation in target
tissues. [114] We tested all these steps from in vitro assays, namely wound healing assay, cell
invasion assay, cell adhesion assay, aggregation assay and MTS assay. Based on our data, δT
inhibited the aforementioned metastasis steps in vitro in a dose- and time-dependent manner
suggesting δT as a potential anti-metastasis facilitator in A549 and H1299 cells.
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The extracellular matrix is proteolytically degraded to allow the migration and invasion of
cancer cells. Single cells, detached from a tumor and released to their intercellular junctions during
metastasis [115], are capable of making cell aggregates. Naturally, non-tumor single cells are
prone to anoikis, a form of apoptosis which is induced by inadequate or inappropriate cell–ECM
interactions or attachments[116]. However, cancer cells show resistance to anoikis; as a result,
they can survive after detachment from their primary site [114]. Cancer cell aggregates exhibit
lower levels of anoikis compare to regular apoptosis. Therefore, the formation of cell aggregates
may induce regular cell apoptosis in cancer cells. However, we observed a dose-dependent
decrease in cell aggregate formation as well as a decrease in adhesion cell adhesion capabilities
with δT treatment. This may have occurred due to a stimulation of anoikis in non-adhesive cancer
cells/ single migrating cells and an induction of regular apoptosis in cell aggregates. Therefore,
future studies are needed to explain δT based apoptosis approaches in A549 and H1299 cells.
Effective cell migration process requires disturbing the interaction between cells and the
ECM. In this process, several proteolytic enzymes (MMP-9) or their activators (uPA) play a key
role in degrading the interaction between cells and the ECM[117]. Thus, identifying new agents
with the capability of inhibiting proteolytic enzymes (MMP9) and/or their activators (uPA) is a
key factor for preventing tumor cell metastasis. Infection with Ad-uPAR-MMP-9 showed a
decrease in the expression of uPa and MMP9 by >90% and also observed reduced levels of cell
invasion in A549 and H1299 cells[97]. In the same study, they showed that inhibition of uPAR
and MMP-9 expression had a more pronounced effect in inhibiting capillary formation in
endothelial cells compared with inhibiting uPAR alone[97]. Also, high expression levels of the
uPA-system and MMP-9 were reported in NSCLC tissue as compared to normal lung tissue[118].
Elevated uPA and MMP-9 expression are also considered as a prognostic biomarker in lung cancer
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[119, 120].This implies the cooperation between uPA/uPAR and MMP-9 is required for lung
cancer metastasis. In our study, we discovered δT inhibits the expression of MMP-9 and uPA does
dependently in A549 and H1299 cells. Some studies have also reported that the anti-metastatic
effect of other nutraceuticals is linked to uPA and MMP9 activity. For example, carnosic acid,
silibinin, curcumin, EGCG, quercetin and baicalein, are some nutraceuticals, which inhibited cell
migration and invasion by downregulating uPA and/or MMP-9 expression in cervical cancer cells,
melanoma cells, human breast epithelial cells, oral cancer cells, and prostate and liver cancer cells,
respectively [121-125]. Consistent with these findings, our results also demonstrated that antimetastastic properties of δT on the inhibition of invasion and migration in lung cancer cells are
due to suppression of uPA /MMp9 expression.
The regulation of uPA/MMP-9 expression involves multiple signaling cascades and
miRNAs. Notch signaling is a signaling system that plays important roles in cell fate decision and
stem cell maintenance in embryonic and postnatal tissues[126, 127]. Lung cancer has shown an
aberrant expression of Notch -1 signaling cascades. Notch-1 inhibition reduces the formation of
brain metastases from breast cancer [128]. Abnormal Notch-1 expression also strongly correlated
with metastatic tumor disease in HCC patients.[129] However, some studies showed Notch-1
signaling acts as a tumor suppressor role in B-cell malignancies [127], neural crest tumors[130],
and skin cancer. Therefore, we can consider that the Notch-1 signaling seems to function as an
oncogene or a tumor suppressor in different types of cancer. In our study, we found that δT dosedependently inhibited the Notch -1 expressions compared to the control. It is well documented that
the activated Notch-1 pathway can increase the expression of its downstream Hes-1 activities. In
this study, δT down-regulated HES-1 protein expression dose dependently alone with Notch -1
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expression in A549 and H1299 cell, which suggests δT as a potential inhibitor for the Notch -1
signaling pathway downstreamly.
Many studies have established that miR-451 is widely dysregulated in human
malignancies, including in lung cancer [131, 132], gastric cancer [133], breast cancer[134], glioma
[135], and leukemia[136], indicating that miR-451 might play a critical role in oncogenesis. The
downregulation of miR-451 was reported in gastric and colon cancers and childhood B-cell
precursor acute lymphoblastic leukemia[137]. miR-451 functions as a tumor suppressor and
regulates survival in NSCLC cells [56]. It is also one of the most down-regulated miR in lung
cancer patients [56]. Our results showed that δT treatment is induced the expression of miR-451
in a concentration-dependent manner in A549 and H1299 cell lines. Moreover, repression of tumor
suppressor miR-451 showed Notch1-induced oncogenesis in T-ALL[136]. Similarly, we observed
that δT inhibited the Notch-1 signaling pathway at the same time with inducing miR 451
expression in A549 and H1299 cells. These results suggest possible cross talk between Notch -1
signaling and miR-451 for regulation of cell migration and invasion in A549 and H1299 cell lines.
In considering the activation of NF-κb, a variety of stimuli from different signaling
pathways are needed. Notch -1, one type of cellular signaling pathway, activates the NF-κb
pathway via its ligands [138]. The down-regulation of Notch-1 has inhibited invasion by
inactivation of NF-κb and MMP-9 in pancreatic cancer cells[139], lung cancer [106] and prostate
cancer[140]. Similarly, we observed that δT inhibited the Notch-1 signaling pathway at the same
time with inhibiting the expression of MMP9, NF-κb, and uPA in A549 and H1299 cells.
Therefore, the results suggest possible cross-talks among Notch -1, NF-κb, MMP9 and uPA for
regulation of cell migration and invasion in A549 and H1299 cell lines.
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These results provide insight into the approach in which δT modulates in vitro invasion
and metastasis in lung cancer. Figure 3.10 shows the proposed mechanism that δT suppresses as
the cell migration and invasion in A549 and H1299 cells. This study suggests that δT as a potential
natural therapeutic approach to prevent lung cancer invasion and metastasis at in vitro level.
Therefore, further studies to establish efficacy of δT in preventing lung cancer migration and
invasion at the animal and clinical level are highly recommended.
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Figure 3.1. Antiproliferative effects of delta-tocotrienol on A549 (A) and H1299 (B) Cells.
Viable A549 (A) and H1299 (B) cell number was determined using the MTS colorimetric assay
after delta-tocotrienol treatment. Both A549 (A) and H1299 (B) were initially plated at a density
of 5 × 103 cells/well (3 wells/group) in 96-well plates and grown in experimental medium
containing 0, 10, 20, 30 µM of delta-tocotrienol for 72 hrs. The vertical bars indicate the mean
absorbance ± SEM (n = 6) where the mean absorbance, represented by different letters, is
significantly different (one-way ANOVA followed by TukeyHSD multiple comparison test, p
<0.05).
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Figure 3.2. Delta Tocotrienol inhibits cell migration and invasion in NSCLC cells.

A549 and H1299 cells were seeded and treated in Matrigel-coated inserts with or without deltatocotrienol. A549 (A) and H1299 (B) cells that invaded the lower surface of the insert over a
period of 20 h were measured from color development after adding MTS . Vertical bars indicate
the mean absorbance ± SEM (n = 3) where mean absorbance, represented by different letters, is
significantly different (one-way ANOVA followed by TukeyHSD multiple comparison test, p
<0.05). A549 (C) and H1299 (D) cells (purple color patches) that invaded to the lower surface
of the insert over a period of 20 h were stained with crystal violet dye and captured from
microscope. Purple color patches indicate invaded cells whereas small dots indicate the pores
in Matrigel surface.
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Figure 3.3. Delta Tocotrienol inhibits A549 (A) and H1299 (B) cell migration dosedependently in wound healing assay.
Dose-dependent inhibition of (A) A549 and H1299 (B), migration by delta-tocotrienol at 0, 10,
20, 30 µM using the wound healing assay. Uniform wounds were created by scratching in
confluent cultures which were treated with delta-tocotrienol over 20 h. Wound healing images
were captured using a microscope at 10× objective.
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Figure 3.4. Delta tocotrienol inhibits cell aggregation in A549 and H1299 cells.
A dose-dependent reduction in no of cell aggregates per cm 2 in A549 (A) and H1299 (B) cells in
cell aggregation assay. Vertical bars indicate the cell aggregates per cm 2 ± SEM (n = 2) where
mean absorbance, represented by different letters, is significantly different (one-way ANOVA
followed by TukeyHSD multiple comparison test, p <0.05). All values are significantly different
with each other (p< 0.05). Photographic view of A549 (C) and H1299 (D) cell aggregates after
treating with/without delta tocotrienol were shown in lower panel.
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Figure 3.5. Delta-tocotrienol inhibits cancer cell adhesion in A549(A) and H1299 cells
A549 (A) and H1299(B) cells were treated with 0, 10, 20, 30 µM concentrations of deltatocotrienol for 18 h and placed into wells precoated with Matrigel®. After 45 min incubation at
37C0, the percentage of adhering cells was determined by the MTS method. The experiments were
repeated three times, each with similar results. Vertical bars indicate the mean absorbance (number
of cells) ± SEM (n = 3) where mean absorbance, represented by different letters, is significantly
different (one-way ANOVA followed by TukeyHSD multiple comparison test, p <0.05).
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Figure 3.6. Effect of Delta -tocotrienols on the expression of MMP-9 enzyme activity in
A549 (A) and H1299(B).
MMP-9 activities of A549 (A) and H1299(B) cells were determined by gelatin zymography
method after treating with 0, 10, 20, 30 µM concentrations of delta-tocotrienol for 72 h. TNFtreated cell medium used as a positive control for this study. A0, A10, A20 and A30 indicates
different treatment concentrations namely 0, 10, 20, 30 µM in A549 cells similarly H0, H10, H20
and H30 indicates same treatment concentrations in H1299 cells.
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Figure 3.7: Down-regulation of Notch-1/uPA pathway proteins by delta-tocotrienol in
A549 (A) and H1299 (B) cells.
A549 (A) and H1299 (B) cells were treated with 0, 10, 20, 30 µM concentrations of deltatocotrienol for 72 h. The expressions of Notch-1, Hes-1, uPA, MMp-9 and Beta actins
protein were detected by western blot analysis.
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Figure 3.8. Delta Tocotrienol inhibits MMP-9 gene expression in A549 (A) and H1299(B) and
increases the miR451 in A549 (C) and H1299 (D).
qRT-PCR analysis was carried out after the cell were treated with or without different doses of delta
tocotrienol. The procedure is described in the “Materials and Methods”. These experiments were
repeated independently three times (for each group, n = 3). Both control and treatment expressions
were relative to those of the internal control gene beta-actin or U-6. The vertical bars indicate the
mean relative expression ± SEM (n = 3) of MMP-9 (relative to B actin) in A549 (A) and H1299(B)
and miR 451 (relative to U-6) in A549 (C) and H1299(D). The mean relative expression, represented
by different letters, is significantly different (one-way ANOVA followed by TukeyHSD multiple
comparison test, p <0.05).
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Figure 3.9. Dose-dependent down-regulation of NF-kB binding activity by delta-tocotrienol
in A549 (A) and H1299(B) cell lines.
A549 (A) and H1299(B) cells were incubated with increasing concentrations of delta-tocotrienol
or DMSO-control for 72 h, and nuclear proteins were extracted and evaluated NF-kB binding
activity in ELISA plate. The vertical bars indicate the mean absorbance ± SEM (n = 6) where the
mean absorbance, represented by different letters, is significantly different (one-way ANOVA
followed by TukeyHSD multiple comparison test, p <0.05).
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Figure 3.10. Proposed mechanism by which delta-tocotrienol suppresses cell migration and
invasion in A549 and H1299 cells.
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CHAPTER 4 1H-NMR METABOLOMICS REVEALS DELTA-TOCOTRIENOL AS A
NOVEL LAT-1 INHIBITOR FOR CONTROLLING GLUTAMINE DEPENDENCE IN
NON-SMALL CELL LUNG CANCER (NSCLC) CELL LINES.
Introduction
Metabolomics, a novel, versatile, and comprehensive approach can provide unbiased
information about the dysregulated metabolites, altered signaling pathways, and their interactions
[26]. The NSCLC metabolome is a potentially informative mirror of the impact of disease and its
dynamics which could lead to promising developments in cancer research, strongly geared toward
the discovery of new biomarkers of disease onset, progression and effects of treatment regimens.
Most current cancer metabolomics studies focus on finding diagnostic biomarkers and
understanding fundamental mechanisms in cancer [26]; nevertheless, this approach could also be
used for identifying the efficacy of treatments. Cell culture metabolomics can be used as a bottomup approach to identify biomarkers of all effects of treatment regimens, [27] and can also be used
to investigate the change in the metabolomics patterns produced due to the introduction of
tocotrienols in NSCLC cell lines.
It is well known that cancer cells, including NSCLC, show aberrant energy metabolism
[141, 142] leading to dysregulation of the metabolome. Healthy cells utilize glucose to produce
ATP (adenosine-triphosphate) through aerobic glycolysis, regardless of oxygen availability, in a
controlled manner, whereas most of the cancer cells access indirect energy sources to support
uncontrolled cell proliferation. Glutamine plays a role as a indirect energy source in NSCLC,
which produces ATP through glutamine-driven oxidative phosphorylation [143]. Extra
consumption of glutamine in tumors is used for generating metabolic precursors for uncontrolled
cell proliferation. These precursors include elevated levels of nucleic acids, lipids, and proteins for
proliferation [144], and increased GSH production for cell death resistance.
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Current research provides further evidence that glutamine in cancer facilitates exchanging
of EAAs (essential amino acids) into proliferating cells via glutamine transporters, which induces
mTOR (mammalian target of rapamycin) activation in NSCLC and other types of cancer [145,
146]. Activated mTOR then promotes protein translation and cell growth via activation of its
downstream genes such as S6k1 and 4EBP1. ASCT2 and LAT1 are the two primary transporters
for glutamine uptake [147, 148]. LAT1 transporter enables transport of the essential amino acids
to enhance cancer cell growth via mTOR-stimulated translation, and ASCT2 maintains the
cytoplasmic amino acid pool to drive LAT1 function [149]. This cooperation of ASCT2 and LAT1
suppresses apoptosis and fuels the energy economy via net delivery of glutamine [149]. Therefore,
inhibiting glutamine uptake via blocking or downregulating glutamine transporters would be an
excellent therapeutic target for NSCLC treatment. The aim of this study was to investigate the
effect of δT on the metabolite dysregulation of glutamine and its derivatives in NSCLS using 1HNMR based metabolomics, with an expression of NSCLC growth, development, glutamine
transporters and mTOR pathway.
Material and Method
Cell culture and treatment with δ-tocotrienol
NSCLC cell lines, namely A549 and H1299, were cultured in RPMI medium (Mediatech,
Manassas, VA) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin in
5% CO2 at 37 C 0. The culture medium was renewed every 2 to 3 days. Adherent cells were
detached by incubation with trypsin-EDTA and centrifuged at 1500 RPM. The treatment media
was prepared by mixing δT (<.01% DMSO as a vector) in the RPMI medium whereas the control
was treated only with RPMI media containing <.01% DMSO. The δT, 10μM, 20μM and 30μM
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concentration containing <.01% DMSO, was chosen as the treatment concentration. δT was gifted
from the American River Nutrition for this experiment.
Intracellular metabolite extraction and determination
A549 and H1299 lines were seeded at a density of 2×106 per 100-mm dishes with for 24
hours followed by replacement of media absent or fortified with different δT concentrations (10
µM, 20 µM, and 30µM) at 37°C. Then, cells were incubated for another 72 hours before extracting
metabolites. For extracting intercellular metabolites, 10 mL of ice-cold ethanol was added and
shaken for 30 min at 4 C0. After 30 min shaking, ice-cold ethanol was transferred into tubes, and
all the extraction solvents were readily removed before NMR analysis by Speed Vac at room
temperature. Then, Intracellular metabolites powder was made by evaporating with ethanol,
redissolved in 450 μl D2O with 0.5 μM 2,2-Dimethyl-2-silapentane-5-sulfonic acid (DSS) and 10
μM imidazole used as a reference for chemical shift and concentration determination. An
additional set of petri dishes was prepared, and samples were normalized to total protein contained
within the additional Petri dishes before using for NMR.
1H- NMR spectroscopy
High-resolution 1H-NMR spectra of intracellular metabolites were obtained on a variant
600 spectrometers operating at 700.13 MHz after normalizing the samples into total protein
concentrations. H-NMR spectra of intracellular extracts were acquired using a 6-kHz spectral
width and 64 K data point. The acquisition time was 5.44 s, relaxation delay 14.56 s, and 64 scans.
1H- NMR spectroscopy processing
After NMR analysis, Free Induction Decay (FID) files were obtained and processed
using NMR processing software ACD (Advanced Chemistry Development, Inc. Toronto,
Ontario, Canada). NMR spectra for all the samples were stacked on top of each other like
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a single batch and processed simultaneously. First, FID files were Fourier Transformed
(mathematical algorithm) to visualize spectra followed by phasing, baseline correction and
binning with the auto option of the software. After completing these steps, the whole
spectra was divided into 1000 bins, giving a numerical value for corresponding peaks and
converted into a data table. The processed data table was used for further statistical analysis
using SIMCA-P + 13.0 multivariate data analysis software (Umetrics, Umea, Sweden).
Multivariate data analysis: PCA, PLS, PLS-DA and OPLS-DA
The Processed NMR spectrum data table from ACD software was imported into the
SIMCA P+ software (Umetrics Academy, Sweden) for Multivariate data analysis (MVDA). After
importing, the data table was transposed and labeled accordingly. The integrals corresponding to
the spectral region from 4.5 to 6 ppm were excluded as this region contains water peaks and
exchangeable protons. Spectral regions displaying no peaks, and some of the very common
spectral regions to all the samples, were also excluded from the data set. After editing,
mathematical models were created based on predictability (Q2) and variability (R2) in the data set
using autofit option in the software. Samples were labeled and colored for identification purposes,
and all data was Pareto-scaled before analysis. Based on the Hotelling T2 test (95 % confidence
interval ) and DMOX

test results, some samples were removed as they were recognized as

extreme outliers for the model.
Principal component analysis (PCA), a classical unsupervised multivariate pattern
recognition method, was used to determine differences in clustering behavior among treated and
non-treated NSCLC cells. Subsequently, PLS-DA, a supervised pattern recognition method, was
further applied to maximize the variation and clustering behavior amongst the groups.
Additionally, OPLS-DA, a supervised pattern recognition method, was performed to maximize the
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variation between groups and to determine the variables that contributed to this variation. The
qualities of models were validated by determining R2 (goodness of fit parameter) and Q2
(goodness of prediction parameter) values and the variables that contributed to this variation.
Finally, by using a partial least square (PLS) regression analysis, we observed a correlation
between the metabolomic profile and anticancer effects, namely anti-proliferation and apoptosis.
The results from PCA PLS, PLS-DA, and OPLS-DA analysis were presented in the score plots,
where each point represents an individual sample (to show the group clusters), and loading plots
or S-plots, where each coordinate represents one 1H-NMR spectral region (to identify the variables
contributing to the classification).
Metabolite identification and quantification from Chenomx NMR suite.
The metabolites spectrum from NMR was identified using Chenomx NMR suite
(CHENOMX INC, Edmonton, Alberta). The fid files from the 1D 1H –NMR spectra were
imported into the Chenomx software. This software has its own processing interface where spectra
were fourier transformed and baseline corrected. Phasing was done using DSS reference peak at
0.0 ppm, and water peak was also deleted. The processed spectra analyzed in the profiler module
of the software. The 600 MHz library with the corresponding pH was selected. Identification and
concentrations of different metabolites were calculated by fitting the set of peaks for those
compounds in the sample spectrum. If the area was crowded with many peaks, then multiple
metabolites were adjusted at one time to match the reference spectrum closest to the sample
spectrum. The identified and quantified compounds were then exported into the Excel sheet.
Statistical analysis and metabolic pathway identification on metabolites
MetaboAnalyst 3.0 software, a web-based metabolomics data processing tool [150]was
use to statistically analyze the metabolites identified from Chenomx NMR suite. Quantified data
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from Chenomx NMR suite was normalized to DSS reference peak at 0.0 ppm followed by range
scaling. T-test was performed, and Manhattan plot and heat maps were generated using Metabo
Analyst 3.0 software. The p-values less than 0.05 were considered statistically significant.
Metabolic pathway identification was performed with the pathway analysis option of
MetaboAnalyst 3.0 software. Briefly, quantified data from Chenomx NMR suite was normalized
to DSS reference peak at 0.0 ppm followed by range scaling. Then, Homo Sapiens pathway library
was selected as a reference, and to generate Pathway Analysis output on all matched pathways, the
pathway analysis was performed according to p values from pathway enrichment analysis and
pathway impact values from pathway topology analysis. Further, metabolites that were changing
most between the control and 30µM treatment were traced back to their origin, and the pathways
were interpreted for metabolism changes using current biochemistry.
Western blot for protein expression analysis
Based on data from Chenomx analysis, altered metabolites were fitted into appropriate
biochemical pathways and dysregulated protein expression associated with altered metabolites
were explored using Western blot analysis. One million cells of each A549 and H1299 were seeded
in 100mm dish per plate and incubated for 24hours; then, the media with/without δT was replaced
with original media and incubated for another 72 hours. Then, the cell was extracted and lysed in
the cold 1X cell lysis buffer (Cell Signaling Technology Danvers, MA) for 30 min on ice with 1X
protease inhibitor (Cell Signaling Technology Danvers, MA) and kept at -80C overnight.
Protein concentrations were estimated by using Pierce BSA Protein Assay kit (Bio-Rad
Laboratories, CA) and 40 µg of total cell lysates mixed with equal amounts of 6x lemma buffer
(Bio-Rad Laboratories, CA), followed by boiling at 100 C for 5 min. Samples were loaded on
10% SDS-polyacrylamide gel electrophoresis, and the gel was electrophoretically transferred to a
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nitrocellulose membrane (Whatman, Clifton, NJ) in transfer buffer (25mM Tris, 190mM glycine,
20% methanol) using a Bio-Rad Trans-Blot® Turbo™ Transfer System. The membranes were
incubated for 1 h at room temperature with 5% BSA in 1x TBS buffer containing 0.1% Tween.
After that, the membranes were incubated overnight at 4C with primary antibodies (1: 1,000). The
following proteins antibodies SLC7A5, SLC1A5, mTOR, S6K and c-MYC (Cell Signaling
Technology, Danvers, MA) were used in the analysis. The membranes were washed three times
with TBS-T and subsequently incubated with the secondary antibodies (1:5,000) containing 2%
BSA for 2 h at room temperature. The signal intensity was then measured by chemiluminescent
image with chemiDoc XRS (Bio-Rad Laboratories, CA).
Results
δT inhibit the cell proliferation in A549 and H1299 cell lines
To further evaluate and validate the antiproliferative effects of δT, an MTS assay was
performed after 72 hours of incubation with 10, 20 and 30μM of δT doses, respectively. We
observed a dose-dependent decrease in cell proliferation of A549 and H1299 cells, and data was
displayed as a whisker plot in figure 4.1.
δT changes metabolite profiles in A549 and H1299 cells
To investigate the changes in metabolism and metabolites with δT intervention,
unsupervised PCA analysis was initially performed using NMR spectral data acquired from
intracellular metabolome of cell lysate. The score plot showed clear separation with different
treatment doses along PC 1 and PC2 in A549 cells, whereas separation was not very clear in H1299
cells (Figure 4.2 AB). When data for all groups were combined in PLS-DA scores, the separation
of the control from different treatment groups further improved at a 2D view of the score plot and

57

58

it validated the impact of δT on cellular metabolite profile of above cell lines in a dose-dependent
manner. (Figure 4.3 AB).
All subsequent analyses were then carried out by separate comparisons of control and
30µM δT treatment after 72 hours incubation using OPLS-DA. The OPLS-DA score plot of
cellular NMR metabolic profile of 30µM δT treated and control cells lines are shown in Figure
04AB. The OPLS-DA score plot exhibited clear segregation between control and treatment groups
in A549 cells and H1299 cells with treatment of δT; the significantly high Q2 indicated a
considerable difference in the cellular metabolic profile of treated cells compared to control cells.
To identify the NMR spectral regions (bins) that varied significantly between control and treated
groups, the loading S-plot from the model was generated. Figure 04 CD shows a representative Splot (correlation of spectral bins with group separation) corresponding to the score plot of Figure
4.4AB. These bins numbers were further analyzed to identify the significant metabolites that
contributed to the separation of the control and treatment groups seen in the OPLS-DA model.
Based on the analysis of S-plot bin numbers, the bin numbers responsible for the differences could
be attributed to glutamine, glutamate and glutathione and lactate in both cell lines.
Cellular metabolites show a significant correlation between anti-proliferative and apoptotic
properties.
The PLS plot (Figure 4.5 ABCD) gives an indication of correlation between metabolite
changes in the cellular metabolome with δT and anti-proliferative and apoptosis effects. The
treatment with δT for 72 hours at various concentrations (10,20,30) induced a significant
coefficient of determination R2 = 0.77 in A549 and R2= 0.49 in H1299 when the data were
correlated with the anti-proliferative effects of δT (Figure 4.5 AB). Furthermore, as determined by
the PLS analysis, apoptotic effects were correlated with the plasma metabolomics profile (R2 =
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0.78 in A549 and R2 = 0.56 in H1299), indicating that δT induces apoptosis in both cell lines
(Figure 4.5 CD).
Quantification of metabolites reveals that δT alter the glutamine metabolism
Chenomx 7.6 Suite NMR software was used to probe the metabolome profiles in treatment
and control groups. H NMR spectra provided information on over 45 metabolites, including amino
acids, intermediates of the tricarboxylic acid cycle (TCA), energy molecules, and nucleic acid
associated molecules (Figure 4.7 AB). Among all the metabolites analyzed, we identified several
metabolites in glutamine metabolism that were significantly decreased (p < 0.05) in the treatment
group as compared to controls (Figure 4.6AB). In addition, we recognize the metabolites such as
leucine and other essential amino acids significantly decreased in both cell lines after δT treatment
(Figure 6AB). Moreover, the metabolites related to cell proliferation such as 2- oxoglutarate,
citrate, and uracil also significantly decreased (p < 0.05) in the treatment group as compared to
controls (Figure 4.6AB).
To recognize the metabolic pathways and biological relevance of the identified
metabolites from chenomix analysis, we performed pathway analysis using MetaboAnalyst 3.0
software [25]. Some of the key altered pathways include lysine biosynthesis, purine metabolism,
alanine, aspartate and glutamate metabolism, D-glutamine and D-glutamate metabolism, Citrate
cycle (TCA cycle) and pyruvate metabolism for both cell lines. The ranking of pathway analysis
is based on statistical p values from enrichment analysis alone with multiple adjustments. The total
number of compounds in the pathway; the hits are the -matched numbers from the uploaded data;
the raw p is the original p-value calculated from the enrichment analysis; the holm p is the p-value
adjusted by holm-bonferroni method; the FDR p is the p-value adjusted using false discovery rate;
the impact is the pathway impact value calculated from pathway topology analysis.
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δT inhibits glutamine transporter (LAT-1) profiles in A549 and H1299 cells
The key differences in metabolite spectrums of glutamine metabolism, leucine, and
essential amino acids were observed in S- plot, Chenomx based quantification of metabolites and
pathway analysis. Thus, we performed a Western blot analysis for protein analysis of mTOR
pathway and glutamine transporters as current literature provides the solid evidence that glutamine
uptake and EAA including leucine are associated with the mTOR pathway activation. Surprisingly,
we observed a dose-dependent inhibition of glutamine transporter LAT-1 and mTOR pathway
proteins (P-mTOR, mTOR, S6K, c-MYC) in the Western blot analysis.
Discussion
In this study, we observed a dose-dependent inhibition of cell proliferation with δT in
NSCLC, namely A549 and H1299. The cumulative evidence shows that the uncontrolled cell
proliferation in cancer cells require macromolecular synthesis to create new biomass, including
DNA, proteins, and lipids [28]. In the proliferating process, glucose based ATP is not the only
production source; glucose and glutamine both provide substrates by supplying both ATP and
carbon skeletons for macromolecular synthesis [29]. Basically, glucose and glutamine contribute
to glycolysis and the TCA cycle where carbon skeletons from glycolysis and the TCA cycle
contribute to macromolecular synthesis for the growing process of the cancers. Glutamine mainly
replenishes the TCA cycle intermediates removed by the process called Glutaminolysis, and for
GSH synthesis in cancer [30, 31]. In the process of Glutaminolysis, glutaminase enzyme (GLS1)
catalyzes the conversion of glutamine to glutamic acid and the subsequent conversion of glutamate
to α-ketoglutarate (2-oxoglutarate), catalyzed by glutamate dehydrogenase [32]. In cancer cells,
the enhanced production of α-ketoglutarate (2-oxoglutarate) from glutamine metabolism can be
observed, as it helps to maintain the citric acid cycle and energy production [32]. Remarkably, in
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the metabolomics analysis of this intervention, we observed a significant reduction of glutamine,
glutamate, and 2-oxoglutarate after treating with 30 µM of δT on NSCLC cells tested (Figure4. 6).
The S-plot from OPLS-DA analysis also showed that glutamine and glutamate concentrations were
the major differences in metabolomes of NSCLC after treating with 30 µM of δT. Further, we
found that some precursors, namely aspartate, glutamine, and uracil (Figure 4.9), needed for DNA
replication were significantly decreased by the δT treatment on NSCLC (Figure 4.6 and Table 4.1).
All this evidence suggests δT may attenuate the glutamine uptake or conversion of glutamate into
α-ketoglutarate where these attenuations of above processes may inhibit the uncontrolled cell
proliferation.
In PLS correlation analysis for both cell lines, the strong correlation between apoptosis
effects and cellular metabolome with increasing δT concentrations were observed in the PLS score
plot. Further, in the previous study, we demonstrated that δT induce apoptosis in a dose-dependent
manner in NSCLC from Annexin based flow cytometry analysis and histone ELISA[24]. The
current literature provides strong evidence that GSH depletion in cancer cells induces apoptosis in
vitro and in vivo[151]. Dalton TP showed GSH-depleted knock-out mouse of γ-GCS died from
massive apoptotic cell death[152]. Further elevated levels of GSH are also connected with
apoptotic resistant phenotypes in several models of apoptosis in previous studies [153, 154], and
GSH depletion by itself has been observed to either induce or stimulate apoptosis [153, 155].
Surprisingly, GSH quantification, after treating with δT in A549 and H1299 cells, shows a clear
decline in intercellular GSH levels in both cell lines (Figure 4.6). The results reveal there may be
an association between GSA levels and induction of apoptosis in NSCLC cells after treating with
tocotrienol.
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The Western blot and PCR data from our previous study revealed that δT dose dependently
inhibits the BCL-2 and BcL-xl expressions in A549 and H1299 cells. Flow cytometry analysis
with Annexing stain also indicated that δT treatment induced apoptotic cell proportion in A549
and H1299 cells [38]. The anti-apoptotic role of Bcl-2 has been linked to GSH content in some
studies. In one study, provoked by GSH-depleting reagents, Bcl-2 overexpression increases GSH
levels and inhibit mitochondrial-induced cell death. [39]. Bcl-2 has also been shown to regulate
GSH content in different cellular compartments [40]. Bcl-2 expressions with decreasing in cellular
GSH concentration is reported in maintaining a high nuclear GSH concentration [41], activating
death receptor induced by apoptotic cascade [42] and generating mitochondrial apoptotic signaling
[43]. Moreover, Bcl-2-mediated resistance to apoptosis was prevented with depletion of
intracellular GSH [44], and anti-apoptotic effect of Bcl-xl has also been attributed to the regulation
of GSH homeostasis by preventing GSH loss. [45] However, these effects seem to be cell typespecific and context-dependent [46]. Thus, decreasing GSH in A549 and H1299 cells after treating
with δT may be attributed to inhibition of the BCL-2 and BcL-xl expression and induction of
apoptosis.
MetaboAnalyst 3.0 online metabolomics data analysis software aided to identify impacted
pathways and networks analysis (Figure 4.8). The key aberrant pathways identified from the above
tool include D-glutamate and Glutamine, alanine, aspartate, glutathione metabolism, and the TCA
cycle, etc. (Figure 4.8). The current literature provides solid evidence that increasing levels of
glutamine were detected in lung cancer tissue especially in non-small lung cancer (NSCLC) when
compared to other cancer types such as colon or stomach cancer [47]. In this study, we compared
glutamine concentrations in cell lysates with 20 reference libraries by using MetaboAnalyst 3.0.
The results from analysis indicated that glutamine and some of the metabolites were lower than
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reference levels in other studies (data is not presented). The reason is that all the databases were
based on urine and plasma glutamine levels, and we extracted metabolites from cell lysates.
All major aberrant pathways included shared metabolites within the network. For instance,
the statistical analysis identified several significant pathways as indicated by low p-value and low
FDR, such as leucine, asparagine, glutathione, glutamate and glutamine. Among the highlyimpacted metabolites, metabolites related to glutamine metabolism were significant. Further,
aberrant glutamine and its related metabolites were also identified in the S-plot of OPLS-DA
analysis. Based on the information in this study, we recognized glutamine and glutamine based
pathways are highly impacted after treatment with δT.
As glutamine plays a key role in normal cell physiology, alterations in glutamine
transporters and metabolizing enzymes that are involved in cancer cells are expected to be highly
impacted [156]. In this study, we found that cellular glutamine levels significantly decrease after
treatment with δTin NMR analysis. This may be due to inhibition of glutamine transporters, and
we thus tested the protein expression levels of glutamine transporters, namely the bidirectional Ltype amino acid transporter 1 (LAT1) and solute carrier family A1 member 5 (SLC1A5) in
Western blot analysis. Above transporters play a fundamental role in glutamine uptake process in
normal cell physiology. LAT-1 also known as SLC7A5/SLC3A2 facilitate glutamine efflux in
exchange for the influx of L-leucine and other essential amino acids (EAA) across the cell
membrane; similarly, SLC1A5 mediates uptake of neutral amino acids including glutamine
[157]. LAT1 expression is a significant element indicating a poor prognosis in various human
cancers including NSCLC [158-162]. We observed dose-dependent inhibition of LAT-1
expressions with δT, whereas SLC1A5 expression was not changed with tocotrienol
concentrations. In addition to facilitating the transport of essential amino acids (EAA) for protein
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synthesis, LAT1 stimulated the growth of cancer cells via mammalian target of rapamycin
(mTOR)[163-165]. mTOR functions include stimulation of cell growth and proliferation by
promoting a variety of anabolic processes, including biosynthesis of proteins, lipids, and
organelles, and limiting catabolic processes such as autophagy [166]. In head and neck squamous
cell carcinoma cell lines, inhibition of LAT-1 transporter using an inhibitor lowered the levels of
phosphorylation of mTOR and its downstream signaling molecules [167]. Similarly, we observed
lower expression of mTOR along with LAT-1 in Western blot analysis after treating with δT. We
quantified EAA including leucine in cell lysates after treating with δTas LAT-1 facilitating
glutamine efflux in exchange for the influx of L-leucine and other essential amino acids (EAA).
Indeed, we observed lower concentrations of EAA including leucine after treating with 30 µm of
δT. Moreover, mTOR functions are mediated by two downstream proteins, the eukaryotic
initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and the p70 ribosomal S6 kinase 1
(p70S6K1, S6K1) [166]. S6K1 is a serine-threonine kinase activated by mTORC1-mediated
phosphorylation, which in turn phosphorylates the 40S ribosomal protein S6, enhancing capdependent mRNAs translation [166]. These two proteins regulate F-actin reorganization, focal
adhesion formation, and tissue remodeling through the proteolytic digestion of extracellular matrix
via up-regulation of matrix metalloproteinase 9 (MMP-9)[168]. Interestingly in our previous study,
we observed δT reduced cell migration, invasion and adhesion in a dose and time-dependent
manner and MMP-9 expressions in NSCLC cell [8]. In summary, we are suggesting that ΔT inhibit
LAT-1 glutamine transporter, which then interferes in glutamine efflux in exchange for the influx
of L-leucine and other essential amino acids (EAA) in A549 and H1299 cells. The interference of
glutamine and EAA exchange result in inhibition of mTOR-1 and its downstream proteins such as
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S6. This inhibition of the mTOR pathway may be one of cause for the inhibited cell proliferation
and induced apoptosis in A549 and H1299 cells.
In the present work, anti-cancer effects of tocotrienols were confirmed by H-NMR
metabolomics analysis. We employed NMR-based metabolomics approaches to reveal metabolism
regulations of tocotrienol on NSCLC, namely A549 and H1229 cell lines. The metabolomics
profiling of NSCLC lysates showed that changes in the glutamine related metabolisms are highly
affected after treating with δT. Further, δT works by inhibiting glutamine uptake into proliferating
cells through glutamine transporter inhibition, thus resulting in inhibition of cell proliferation and
induction of apoptosis via downregulation of the mTOR pathway. Through this work, NMR-based
cellular metabolomics proves possible capacities for evaluating the therapeutic effect of
phytochemicals/ bioactive and reveal holistic regulations on mechanisms.
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Figure 4.1 : Antiproliferative effects of tocotrienol on NSCLC cells. Cell viability of human
NSCLC cell lines A549 (A) and H1229 (B) cells.
Both A549 and H520 cells were initially plated at a density of 5 × 10 3 cells/well (5 wells/group)
in 96-well plates and grown in experimental medium containing 0, 10, 20, 30 µM of δT
treatment media for 72 h. Viable cell number was determined using the MTS colorimetric assay.
Absorbance data from MTS data further analyzed using metalanalystat software, and above
whisker plots were generated.
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Figure 4.2:Effects of δT on A549 (A, C) and H1299 (B, D) on the metabolome of lung
cancer cell lines.
Principal component analysis (PCA) scores plot( A and B), PC1 (t[1]) versus PC2 (t[2]) showing
the unsupervised separation of metabolites profiles among the δT treatments 0(Green), 10(blue),
20(Red),30 (yellow) after 72 hours incubation. Each symbol represents metabolites from the one
Petri dish described at the method section; The ellipses shown in A and B represents the Hotelling’s
T2 95% confidence interval for the multivariate data. Data is parito scaled and mean centered.
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Figure 4.3: PLS-DA scores plots of A549( A) and H1299 (B) lung cancer cell line
metabolomes after treating with/without δT for 72 hours.
Partial least squares Discriminant Analysis (PLS-DA) scores plot( A and B), PC1 (t[1]) versus
PC2 (t[2]) showing supervised separation between the four sample classes based on the δT
treatments namely 0(Green), 10(blue) , 20(Red),30 (yellow) after 72 hours incubation period .
The ellipses shown in A and B represents the Hotelling’s T2 95% confidence interval for the
multivariate data. Details of the experimental procedures are given in Materials and Methods.
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Figure 4.4: OPLS-DA analysis of A549 and H1299 the metabolome of lung cancer cell
lines after treating with/without δT for 72 hrs.
OPLS-DA score plot based on the cellular metabolic profiling of lung cancer cells lines
namely A549 (A) and H1299 (B), 30µM treatment (Green) and control (Yellow); the results
indicated that cellular metabolic profiling of lung cancer cells lines was significantly changed
after δT treatment for 72 hours. The S-plots of OPLS-DA analysis of A549(C) and H1299 (D)
from Treatment (30µM) and control (0µM) cells. The axes plotted in the S-plot from the
predictive component are p [1] vs. p(corr) [1], representing the magnitude and reliability,
respectively. Variables in labeled compound name could be exploited as potential biomarkers.
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Figure 4.5: Correlation of lung cancer cell line’s metabolomes (with/without tocotrienol)
between antiproliferative and apoptosis effects.
Changes in the metabolomic score values ([t1] or[t2]) of individual cells treated with/without δT are
plotted along with the corresponding anti-proliferative and apoptosis effects ([u1] or [u2]), as
determined by the PLS analysis. The coefficient of determination (R2) among ([t1] or [t2]) and ([u1]
or [u2]) that was calculated after linearization of the relationship is indicated. The relationship
between the cellular metabolomic profile with/without δT and antiproliferative in A549 (A)
(R2 = 0.7) and H1299 (B) (R2 = 0.7) 3b. The relationship between cellular metabolomic profile
with/without δT and apoptosis effects in A549 (A) (R2 = 0.7) and H1299 (B) (R2 = 0.7). Each
symbol in different colors namely 0(Green), 10(blue), 20(Red), 30 (yellow) represents metabolites
from the one Petri dish described at the method section;
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Figure 4.6: The effects of δT on a cancer cell metabolites were measured with H-NMR and
analyzed in Chenormix and MetaboAnalyst 3.0 software.
The Important metabolites selected by t-tests with threshold 0.05 in Manhattan Plot (A) A549 and
(B) H1299. The red circles represent features above the threshold. The p values are transformed
by -log10 so that the more significant features (with smaller p values) is plotted higher on the
graph. The table below shows the detailed results from the T-test. The number in table is
correspondence to the metabolites label in in Manhattan Plot.
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Table 4.1: List of Significantly impacted metabolites in NSCLS after δT treatment
The table below shows the detailed results from the T-test in (A) A549 and (B) H1299. The
number (#) in table is correspondence to the metabolites labeled in Manhattan Plot figure 4.6.
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Figure 4.7: Heat map of metabolites significantly differentially expressed between
control and treatment in lung cancer cell lines.
The metabolites are detected at chenomix software analysis of NMR spectrums of A549 cells
(A) and H1299 (B) after incubating with or without δT for 72 hours. Each column represents a
sample, and each row represents the expression profile of metabolites. The fold changes from
the overall mean concentration are shown in a color-coded way. Blue color represents a
decrease, and red color an increase. The very Top row with Green color indicates the control
samples and red color row indicates the samples with the 30µM treatment of δT.
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A.

B.

Figure 4.8: The most predominant altered metabolic pathways and the biochemical linkage
among the metabolites were analyzed by pathway analysis of MetaboAnalyst 3.0 in A549
(A) and H1299(B) cell lines after treating with/without δT for 72.
The Ranking of pathway analysis is based on statistical p values from enrichment analysis alone
with multiples multiple adjustments. The Total is the total number of compounds in the pathway;
the Hits is the matched number from the uploaded data; the Raw p is the original p-value
calculated from the enrichment analysis; the Holm p is the p-value adjusted by Holm-Bonferroni
method; the FDR p is the p-value adjusted using False Discovery Rate; the Impact is the pathway
impact value calculated from pathway topology analysis.
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Figure 4.9: Effect of δ- tocotrienol on expressions of the mTOR pathway and glutamine
transporters.
A549 (A) and H1299 (B) cells were treated with varying concentrations of δT for 72 h. The
expressions of protein were detected by western blot analysis including mTOR, LAT-1,
SLC1A5, S6K1, and B-Actin.
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Fig 4.10. Effect of δT on glutamine transporters, mTOR pathway and glutamine
metabolism.
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CHAPTER 5 TOCOTRIENOLS RICH MIXTURE INHIBITS CELL PROLIFERATION
AND INDUCES APOPTOSIS VIA DOWN-REGULATION OF THE NOTCH-1/NF-ΚB
PATHWAYS IN NON-SMALL CELL LUNG CANCER CELLS (NSCLC).

Introduction
Tocotrienols and tocopherols together comprise vitamin E. Most commercially available
vitamin E supplements contain tocopherol isomers as their key active ingredient. However, studies
have shown that tocotrienols are more potent in their antioxidant and antitumor properties [169].
Tocotrienol isomers namely α, β, γ, and δ are found naturally in cereal grains, vegetable oils, and
palm oil, and have demonstrated a strong association with the prevention of cancer and inhibition
of tumors, both in vitro and in vivo [170]. Tocotrienols have displayed anti-tumor effects on
different human cancer cells including prostate, breast, colon, melanoma, and lung, via induction
of apoptosis by inhibiting multiple signaling pathways including the Notch and NF- κB pathway.
Our previous work clearly showed that δT inhibits NF- κB signaling pathways via down-regulation
of Notch-1, thereby inhibiting the proliferation, metastatic potential while inducing apoptosis of
NSCLC adenocarcinoma cells in a dose-dependent manner [8, 24, 107, 171]. However, overall
effects of tocotrienols on NSCLC are still not well understood.
Using δT to treat cancer is not efficient since it is both difficult to isolate and expensive.
In addition, individual isomers are not currently available in quantities required for animal or
clinical studies. Thus, it becomes necessary to investigate the therapeutic targets of naturally
available tocotrienols rich mixtures. The present study aims to investigate the effect of
commercially available tocotrienol rich mixture in capsules (TRMC) extracted directly from palm
oil with the working hypothesis that this treatment would inhibit NSCLC cell proliferation and
induce apoptosis by inhibition of Notch-1 signaling via the NF-kB pathway.
Materials and Methods
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Cell culture and treatment with tocotrienols
Two different NSCLC cell lines, representing squamous cell carcinoma (H520) and
adenocarcinoma (A549), were cultured in RPMI medium (Mediatech, Manassas, VA)
supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin in 5% CO2 and
37°C 0. Tocotrienols rich capsule, a gift from Carotino (Kuala Lumpur, Malaysia), containing 21.3
% tocopherol and 78.7% tocotrienol, were used in this study. Tocotrienols in the capsule consist
of 26.7% α-tocotrienol, 3.3% ß-tocotrienol, 38.1% ƴ-tocotrienol and 10.6% δ-tocotrienol whereas
the remainder 21.3% is α- tocopherol isomer. The medium containing DMSO (vehicle control) or
different concentrations of TRMC diluted from a 100mg/mL stock solution were used as
experimental treatment media for cell culture. The final concentration of treatment media is
expressed as amount of TRMC (ng) in l mL of RPMI media (ng/mL).
Anti-proliferative effects of TRMC
The anti-proliferative effects of TRMC on NSCLC cell lines were analyzed using MTS
assay. 5x105 of A549 and H520 cells were seeded in a 96-well plate and incubated overnight.
After incubation, the medium was replaced, and cells were treated with fresh medium containing
< 0.10% DMSO (control) and different concentrations of TRMC (treatment). After 72 hours of
treatment, 20µl of Cell Titer 96 Aqueous One. Solution Reagent from Promega, (Madison, WI)
was added to each well and incubated for 2-hour at 37°C in a humidified, 5% CO2 atmosphere.
Then absorbance at 490nm was measured using the Bio-Tek ELx800 plate reader (Winooski, VT).
Each variant of the experiment was performed in triplicate.
In colongenic assay, 1 x 105 of A549 and 1 x 10 6 of H520 cells were seeded in 100mm
dish and incubated overnight. Subsequently, culturing media was replaced with treatment
(different concentrations of TRMC) and control medium and then incubated for another 72 h. The
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viable cells were counted by an automated cell counter (Innovating Standards, USA) and 2000
cells were transferred per 100mm dishes with 10mL growing media. Then, cells could grow for
25 days at 37C0 in a 5% CO2 incubator. After subsequent incubation, all the colonies were fixed
in 4% Paraformaldehyde and stained with 2% crystal violet.
Cell death detection
Cell death detection histone /DNA ELISA Kit from Roche (Palo Alto, CA) was used to
detect apoptosis in NSCLC cells. 1 x 105 of A549 and 1 x 10 6 of H520 cells were seeded into
six-well plates. After an overnight incubation, cells were treated with control medium or treatment
medium (different concentrations of TRMC) for 72 hours. Cytoplasmic histone/DNA fragments
were extracted from lysed cell extract and incubated in microtiter plate modules coated with antihistone antibody. Next, peroxidase conjugated anti-DNA antibody was used to detect the
immobilized histone/DNA fragment. Bound antibodies were detected by the intensity of color
development in microtiter plate modules, after washing with ABTS substrate. The absorbance of
the samples was measured at 405nm using the Bio-Tek ELx800 plate reader (Winooski, VT).
Annexin V-FITC apoptosis detection kit (BD, San Jose, USA) was used for apoptosis
analysis. A549 and H520 cells were incubated in the control or treatment (0.6ng/mL concentration
of TRMC) media for 72 h. After, cells were extracted by scraping and collected to ice-cold PBS.
Then, cells were spun down and resuspended in 1x binding buffer at a concentration of 105 /ml
cells in a total volume of 100 µl. Subsequently, five µl of Annexin V-FITC and five µl of PI
(Propidium Iodide) were added. All cells were kept in the dark for 20 min at room temperature.
Finally, 400 µl of 1X binding buffer was then added to each tube, and the number of apoptotic
cells was analyzed by flow cytometry (BD, San Jose, CA).
Cell migration assay
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A549 and H520 cells were seeded in a six-well plate at the concentration of 2 X 105 and 1
X 10 6 cells per well respectively. After the cells had been incubated for 36 hrs., the media was
removed, and a scratch wound across each well was made using a 100ul pipette tip. All the wound
areas were washed with PBS three times to ensure that no loosely held cells were attached. The
width of the scratch was imaged and measured by a Nikon H 600L microscope connected to the
camera at five places along the scratch. Subsequently, the cells were cultured in control or
treatment media (different concentrations of TRMC) for 30 hrs. Then the width of the scratch was
reimaged and measured to find the progress of cells that had migrated into the wound.
Cell invasive assay
The tumor invasive ability in the above cell lines was assessed by BD Biocoat invasion kit
(BD, San Jose, CA). 2.5 x 105 A549 cells and 5 x 105 H520 were seeded with basal media in each
six well upper chamber in the presence or absence of treatment media (different concentrations of
TRMC). In the meantime, 3ml of culture medium with 10% FBS was added to each lower chamber
of the six-well plate. After a 20 h incubation, the cells in the upper chamber were removed using
a cotton swab. Then cells were fixed in 4% Paraformaldehyde and stained with 2% crystal violet.
Then cell unbound crystal violet was washed with PBS before they dried. After that, the stained
crystal violet (cell bound) was washed with 20 % acetic acid, and then the absorbance of the
dissolved crystal violet was measured at 405nm using the Bio-Tek ELx800 plate reader (Winooski,
VT). Each experimental condition was performed in triplicate.
Real-time quantitative PCR for gene expression analysis
One million A549 and H520 cells were seeded in 100mm dish per plate and incubated for
24 hours. Subsequently, culturing media was replaced with treatment (different concentrations of
TRMC) or control medium and then incubated for another 48 h. Total RNA was isolated using
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RNeasy Mini Kit from QIAGEN (Valencia, CA) according to the manufacturer’s protocols.
1000ng of total RNA from each sample was subjected to the first strand cDNA synthesis using
High Capacity RNA to cDNA master mix (Applied Biosystems, Foster City, CA) in a total volume
of 50 µl. qRT-PCR was performed to explore the Notch-1expression. Diluted cDNA (2 uL) and 2
uL of each reverse primer (5′-GTT GTA TTG GTT CGG CAC CAT-3′) and forward primer ( 5′CAC TGT GGG CGG GTC C-3′) and 12.5 uL master mix (SYBR GREEN PCR Master Mix;
Applied Biosystems, Warrington, UK) were used in each 25 uL PCR reactions performed in
Eppendorf Master cycler realplex 4 (Eppendorf, Hauppauge, NY) at 25C for 10 min, followed by
48 C0 for 30 min and 95 C0 for 5 min. Expression values were normalized with a β-actin.( sense
(5′-ACCAACTGGGACGACATGGAGAAG-3′;

antisense

(5′-

TACGACCAGAGGCATACAGGGACT-3′)). Each gene expression was tested in triplicate.
Western blot for protein expression analysis
Western blot analysis was performed as part of a protein expression analysis using the
following antibodies: Poly (ADP-ribose) polymerase (PARP), b-actin, Survivin, Bcl-XL and
Notch 1(Cell Signaling Technology, Danvers, MA) in cell signaling pathways. One million A549
and H520 cells were seeded in a 100mm dish per plate and incubated for 24hours. Then cells were
treated for 72 hours with treatment (different concentrations of TRMC) and control medium and
incubated for 72 h. Cells were lysed in the cold 1X cell lysis buffer (Cell Signaling Technology
Danvers, MA) for 30 min on ice with 1X Protease inhibitor (Cell Signaling Technology Danvers,
MA). Then protein concentrations were calculated by using Pierce BSA Protein Assay kit (BioRad Laboratories, CA). Subsequently, 50 mg of total cell lysates were mixed with equal amounts
of 4X lemma buffer (Bio-Rad Laboratories, CA) and samples were loaded on 10% SDSpolyacrylamide gel electrophoresis. After electrophoresis, the gel electrophoretically was
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transferred to a PVDF (Trans-Blot Turbo Mini PVDF system, Bio-Rad) using Trans-Blot®
Turbo™ Transfer System (Holliston, MA). The membranes were incubated for two hours at room
temperature with 5% Casein. After that, membranes were incubated overnight at 4C˚ with primary
antibodies (1: 1,000-4000). The membranes were washed three times with TBS-T and
subsequently incubated with the secondary antibodies (1:5,000) containing 2% BSA for two h at
room temperature. The signal intensity was then measured by a chemiluminescent imager with
chemiDoc XRS (Bio-Rad Laboratories, CA).
NF-κB filter plate assay for measuring NF-κB binding activity
NF-κB filter plate assay kit was obtained from Signosis (Sunnyvale, CA) and used to
determine the NF-κB DNA binding ability of each sample. A549 and H 520 were seeded in petri
dishes and incubated for 24 hours. Cells were then treated with or without different concentrations
of TRMC. After 72 hours of treatment, cells were collected and washed, and nuclear protein
extraction was performed with a NE- PER

®

Nuclear and Cytoplasmic Extraction reagent kit

(Thermo Scientific, USA) according to the manufacturer’s protocols.
Protein concentrations were determined using the Pierce BCA protein assay kit (Rockford,
IL). Standard samples were prepared according to the manufacture’s protocol. The absorbance of
both standards and samples was measured at 562nm using a UV-1800 spectrophotometer from
Shimadzu Scientific Instruments (Kyoto, China). The assay was conducted according to the
protocol using a biotin-labeled DNA sequence of NF-κB mixed with 3µg of nuclear extract to form
an NF-κB-DNA binding complex. For each sample, 10µl TF binding buffer mix, 2µl NF-κB probe,
3µg and distilled water was added to bring the total volume up to 20µl. A filter plate was used to
retain bound NF-κB probe, while the unbound NF-κB probe was filtered out. The bound, prelabeled NF-κB probe was then eluted from the filter, collected and transferred to a hybridization
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plate for quantitative analysis. NF-κB probe was further detected using streptavidin-HRP, and
luminescence of the probe was measured using an Ultra Multifunctional Microplate Reader from
Tecan (Vienna, Virginia).
Data analysis
Significant difference between treatment and control groups was analyzed using a one-way
ANOVA (eZanova , USA). Values of <0.05 were considered statistically significant.
Results
Anti-Proliferative effect of tocotrienols on A549 and H520 Cells
To evaluate and compare the cell viability and proliferative effects after in vitro exposure
of tocotrienols, MTS and the traditional clonogenic assays were used. Results from the MTS assay
showed a dose-dependent decrease in cell growth and proliferation for both A549 and H520 cells.
A549 cells on treatment with 0.04, 0.08, 0.12 and 0.16 ng/mL concentrations of TRMC
demonstrated 13, 15, 38 and 88% cell growth inhibition respectively, relative to control, after 72
hours’ incubation (Figure 5.1-A). Similarly, the H520 cell line on treatment with 0.04, 0.08, 0.12
and 0.16 ng/mL concentrations of TRMC also exhibited a respective 0, 12, 33 and 84 % cell growth
inhibition relative to control at same conditions (Figure 5.1-B). Inhibition of cell growth was
significant at every concentration for A549 cells and for H520 cell inhibition was significant at a
concentration of TRMC above 0.08 ng/mL.
The clonogenic assay was performed to investigate the enduring proliferative effect of
tocotrienols. Exposure of TRMC on A549 and H520 cells for 72 h irreversibly inhibited 80%
clonogenic growth compared with untreated cells (Figure 5.1 CD). For both cell lines, colony
formation was greatly reduced at 0.12 ng/mL of TRMC. In this study, there were similar trends in
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both MTS and clonogenic assays, suggesting that the commercially available mixture of
tocotrienols from capsule significantly inhibited the growth of NSCLC cells.
Tocotrienols induce apoptosis in lung cancer cell lines

Histone/DNA ELISA assay and Annexin V/PI staining were used to evaluate the apoptotic
effects of TRMC on A549 and H520 cells. Results from ELISA showed significantly increased
apoptosis with concentrations of TRMC on A549 cells and H520 cell lines (Figure 02-AB). To
further confirm the results from our histone ELISA data, flow cytometry based quantification was
performed after Annexin V/PI staining. Quantitation of apoptotic cells from flowcytometry
analysis after treatment with 0.06ng/mL of TRMC for 72 hours showed increased apoptosis in
both cell lines (Figure 5.2 CD). Thus, these outcomes evidently suggested that tocotrienols caused
a statistically significant increase in the percentage of apoptotic cells in lung cancer cell lines.
Inhibition of cell invasion and migration by tocotrienols
The effect of TRMC on tumor cells invasion and migration were evaluated using Matrigel
invasion and wound healing assays. TRMC concentrations (0.4-0.12 ng/mL) resulted in significant
decreased penetration of lung cancer cells through the Matrigel-coated membrane as compared
with the control cells (Figure 5.3 AB), confirming TRMC reduced the invasion capacity of lung
cancer cells. For further confirmation of anti-migratory effects of TRMC, the wound healing assay
was performed. The results of the wound healing assay revealed that there was reduced cell
migration from custom made wounds with 0.8ng/mL of TRMC after 30 hrs. incubation (Figure
5.3 CD). However, wound healing was significant without TRMC at same incubation conditions.
Down-regulation of the Notch-1 and its target genes expressions by tocotrienols
Investigations of molecular mechanisms behind tocotrienols inhibited cell growth, induced
apoptotic cell death, cell invasion and migration in NSCLC cells were evaluated using RT-PCR
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and western blot analysis. Dose-dependent response of TRMC showed a significant decrease in
Notch-1 m-RNA expressions in A549 and H520 cells after incubating 48 hours (Figure 5.4 AB).
Moreover, results from protein expressions in Notch -1 downstream genes, namely HES 1, BcLXL and Survivin, PARP, were given a dose-dependent decrease with TRMC in western blot
analysis (Figure 5.5).
Inhibition of NF-κB DNA-binding activity with tocotrienols
NF-κB and Notch pathways have shown cross talks in many types of cancer including lung
cancer [1,2]. Thus, we explored whether the downstream effect of Notch-1 down-regulation was
mechanistically linked to the NF-κB pathway. Nuclear proteins from treated and control cells from
A549 and H520 were analyzed for NF-κB DNA-binding activity as measured by NF-κB Filter
Plate Assay. As demonstrated in Figure 6 A and B, compared to the control, TRMC significantly
inhibited the DNA-binding activity of NF-κB for both cell lines.
Discussion
Despite new findings in molecular pathways involved in lung cancer biology and the
application of new therapeutic results, NSCLC remains one of the foremost reasons for cancer
deaths worldwide [172]. The treatment methods currently available for lung cancer include
surgery, target therapy, and different modalities of chemotherapy and radiation therapy. However,
these treatment methods have not significantly impacted the five-year survival rate of NSCLC over
the last four decades[173]. Poor survival rates are mainly attributed to late diagnosis and tumor
metastasis and current chemotherapeutic drugs also have resulted in several side effects, drug
resistance, and recurrence among treated NSCLC patients[173]. Therefore, new therapeutic
modalities with minimal side effects are urgently needed in improving the treatment outcome to
include better long-term survival of patients diagnosed with lung cancer.
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PCR and western blot data from in this study clearly demonstrated that TRMC targeted
and dose-dependently inhibited expression of Notch-1 in A549 and H520 cell lines. Aberrant
expression of Notch has been reported in many types of cancer, including pancreatic, colon, lung,
cervical, breast, and skin cancers[174-179]. Notch signaling is also reported to play important roles
in regulating cancer cell proliferation, differentiation, invasion, and apoptosis[180-183]. Aberrant
Notch 1 expression also exhibited tumor promotion under hypoxia conditions in lung cancer[184].
In another clinical study, Notch 1 expression levels were varying from low to high in some NSCLC
patients, and Notch 1 expression was found to be associated with TNM stage in histological
grading,[185] suggesting Notch 1 may play key roles in the advancement of NSCLC. Remarkably,
we observed TRMC inhibited the cell proliferation dose-dependent manner in MTS and
Clonogenic assay alone with Notch-1 inhibition, suggesting that expression of Notch-1 with
TRMC may prevent the advancement of A549 and H520 cells. In our previous studies, we clearly
demonstrated that δT inhibit cell proliferation by inhibiting different therapeutic targets including
Notch-1 [8, 24, 107, 171]. Therefore, TRMC could be a potential Notch-based therapeutic target
therapy method in preventing NSCLC.
Furthermore, blockage of the Notch pathway using γ-secretase inhibitor suppressed
osteosarcoma growth in vitro and in vivo [186, 187]. Preclinical studies also showed the
therapeutic efficacy of Notch inhibitors against NSCLC in some studies[188]. Stabilized peptides
was another approach which interferes with receptor/ligand interactions in Notch signaling
pathway [189]. Although these approaches have shown potential in inhibiting Notch-1
expressions, their inhibitory potential has not been evaluated at a clinical level, warranting the
importance of exploring novel natural Notch-1 inhibitors with minimal side effects. In this study,
we used TRMC which is directly isolated from palm oil with minimum processing. Tocotrienols
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have been widely consumed by humans for a long time, and GRAS status for tocotrienols is also
granted by FDA [190] . Thus, our approach on inhibition of Notch-1 using TRMC could be a
promising strategy to achieve better treatment outcome with minimum side effects for NSCLC
patients.
We further observed that TRMC dose-dependently inhibited the HES-1 expressions in
A549 and H520 cell lines. It is well documented that Hes-1 is a transcriptional target of the Notch
signaling pathway [191], suggesting TRMC dose dependently inhibits the Notch-1 pathway in a
downstream manner. Further insight into the molecular mechanism of Notch 1 pathway and its
target genes, Notch-1/Hes-1 pathways have been reported to be upstream to NF- κB activation in
lung cancer and leukemia cells [24, 192]. In this study, the results from NF- κB filter plate assay
clearly showed a dose-dependent decrease in NF- κB DNA-binding activity in A549 and H520
cell with different concentrations of TRMC. According to current evidence, Notch ligands induced
NF-κB activation in leukemia cells and decreased Notch-1 lowered NF-κB DNA binding activity
[193]. Another study also reported that mice with reduced Notch activities had significantly
decreased NF-κB activity [194]. Schwarzer1 et al. reported Notch had exerted its effects through
regulation of NF-κB in human lymphomas [195]. Our previous study also demonstrated the cross
talk between the Notch pathway and NF-κB pathway in adenocarcinoma lung cancer cell lines,
which was induced by δT [8, 24, 107, 171]. Therefore, our data alone, in conjunction with current
evidence, strongly supports that TRMC inhibits notch-1 mediated NF-Kb pathways.
TRMC induced apoptosis in A549 and H520 cells dose dependently in this study. The
TRMC consisted of α-tocotrienol, ß-tocotrienol, ƴ-tocotrienol and δ-tocotrienol isomers. Some
studies have shown that ƴ-tocotrienol induced apoptosis in neuroblastoma SH-SY5Y cells[196]
and human gastric cancer cells [79]. In our previous study, we clearly showed δT induced the

88

apoptosis in NSCLC in a dose and time-dependent manner at 10 -30 µM concentration range. In
another study, gamma and δT exerted a more potent anticancer effect on breast cancer cell lines as
compared to α-tocotrienol[197]. Numerous results from recent studies on tocotrienols also
indicated that γ- and δ-tocotrienols exhibited greater anticancer activity than α- or β-tocotrienols;
where δT shows a higher efficacy and effectiveness in the induction of apoptosis in both A549 and
U87MG cancer cells as compared to alpha- and gamma-tocotrienols [109]. Therefore, induction
of apoptosis in A549 and H520 cells with TRMC could be the result of individual γ- and δtocotrienol isomers, or from their cumulative effects.
Bcl-2 and Bcl-XL inhibitor proteins play a significant role in apoptosis [70, 198]. We
observed a dose decrease in Bcl-2 gene expression by PCR and Bcl-XL protein expression by
western blot analysis. Also, we found inhibition of survivin protein with TRMC in Western blot
analysis where survivin, a member of the inhibitor of apoptosis, inhibited caspase activation,
thereby leading to negative regulation of apoptosis [199]. Moreover, a down-regulation of Notch1 was observed to decrease Bcl-XL apoptosis protein expression in pancreatic cancer cells. In
breast cancer, down-regulation of Notch-1 is associated with the lower expression of Bcl-2 and
Bcl-XL [200]. Activated Notch-1 pathway can increase the expression of survivin expression
[201]. Furthermore, Survivin, Bcl-2, and Bcl-XL are downstream targets of the NF-Kb in several
cancers cells. Consistent with above, we suggest that TRMC inhibits survivin, Bcl-2, and Bcl-XL
via down-regulation of Notch-1 and NF-Kb that it lead in inducing apoptosis in NSCLC.
Further studies need to be done to assess the anti-cancer activity and bioavailability of
vitamin E capsules that are readily available. Bioavailability is always a potential concern for all
nutraceuticals. Although in vitro experimental evidence has been very promising, oral
supplementation of tocotrienols in animal and human studies has produced varying results [202].
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Oral absorption of tocotrienols into the circulation is mediated by a carrier transporter system that
displays saturation and down-regulation when exposed to high concentrations of tocotrienols [24,
202]. To compensate for these limitations in oral absorption of tocotrienols, investigators have
developed new derivatives and nanoparticle delivery systems that significantly enhance tocotrienol
bioavailability and, therefore, the therapeutic effects of tocotrienols on cancer [202]. In addition
to bioavailability, timing and dosage are also concerns, and these factors will be different for cell
cultures versus animals versus humans. Further experiments need to be conducted to investigate
whether this capsule can show the same results in animals before it can be taken to a human trial,
which is the ultimate goal.
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Figure 5.1: Antiproliferative effects of TRMC on A549 (A) and H520 (B) cells were
determined using MTS assay.
Both A549 and H520 cells were initially plated at a density of 5 × 103 cells/well (3 wells/group) in
96-well plates and grown in experimental medium containing 0, 0.04,0.08, 0.12 and 0.16 ng/mL of
TRMC for 72 h. Viable cell number was determined using the MTS colorimetric assay. Vertical
bars indicate the mean absorbance ± SEM (n = 3) where mean absorbance, represented by different
letters, is significantly different (P < 0.05). Cell survival of human NSCLC cell lines, A549 (C) and
H520 (D) cells, in clonogenic assay. A549 and H520 cells treated with different concentration of
TRMC (0, 0.04, 0.08, and 0.12 ng/mL) were evaluated by the clonogenic assay. The
photomicrographic difference in colony formation in A549 and H520 cells untreated and treated
with TRMC are shown.
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Figure 5.2: Apoptotic effects of TRMC on A549 (A) and H520 (B) were determined using
histone/DNA ELISA.
Cells were treated with increasing concentration of TRMC for 72h. Vertical bars indicate the
mean absorbance ± SEM (n = 3) where mean absorbance, represented by different letters, is
significantly different (P < 0.05). Apoptosis of A549 (C) and H520 (D) cells were determined by
Annexin V-FITC based flow cytometry analysis. Cells were treated with 0.6ng/mL of TRMC for
48 h and Apoptotic cells were detected from flow cytometry. Quadrant with (*) indicates early
apoptotic cells after with or without treatment.
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Figure 5.3: TRMC inhibits cell migration and invasion in NSCLC cells.
A549 (A) and H520 (B) cells were seeded treated seeded into Matrigel-coated inserts with TRMC or
DMSO. Cells that invaded the lower surface of the insert over a period of 20 hours were stained with
crystal violet dye, followed by the absorbance reading. Vertical bars indicate the mean
absorbance ± SEM (n = 3) where mean absorbance represented by different letters is significantly
different (one-way ANOVA followed by Dunnett’s multiple comparison test, p <0.05). (C and D),
dose-dependent inhibition of NSCLC cells migration by TRMC using the wound healing assay.
Uniform wounds were done by scratching in confluent cultures which were treated with TRMC over
30 h. After that, the wound healing images were captured using a microscope at 10× objective.
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Figure 5.4: Dose-dependent down-regulation of Notch-1 gene expression by TRMC.
A549 (A) and H520 (B) cells were treated with or without TRMC for 72 h. Data are
expressed as delta CT values normalized against β-actin (mean±SE).
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Figure 5.5: Down-regulation of Notch-1, Hes-1, PARP, Survivin and BCL-2 by
TRMC.
The expressions of protein were detected by western blot analysis in A549 (A) and H520 (B) cells
after treating with or without TRMC for 72 hours.
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Figure 5.6: Dose-dependent down-regulation of NF-κB DNA Binding
Activity by TRMC.
A549 (A) and H520(B) cells were incubated with increasing concentrations of
TRMC or DMSO-control for 72 h, and nuclear proteins binding activities were
evaluvated by ELISA Vertical bars indicate the mean absorbance ± SEM (n = 3)
where mean absorbance represented by different letters is significantly different
(one-way ANOVA followed by Dunnett’s multiple comparison test, p <0.05).
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS
NSCLC has shown a 5-year survival rate of 50% at early stages, but the rate is significantly
reduced to less than 5% for cases diagnosed with distant metastasis in late stages. The current
evidence clearly suggests that MMP-9 mediated metastasis is one of the key invasion and
metastasis factors in lung cancer patients. In this study, we clearly showed that δT inhibits MMP9 expression along with its key functions namely cell migration, cell invasion, cell adhesion, cell
aggregation and cell proliferation. We also explored the underlying mechanism for those
regulations as suppression of Notch-1 activation through reducing translocation to the nucleus and
DNA-binding activities of NF- κB, leading to the down-regulation of uPA and MMP-9 expression.
Further, δT induced the miR 451 expression in A549 and H1299 cells which show possible
crosstalk between miR 451, Notch -1 and NF- κB. Thus, we can suggest that δT inhibits the MMP9 mediates cell metastasis in vitro. However, further studies on the effect of δT on animal models
and a human clinical trial are need be established to understand the efficacy of δT in inhibiting
metastasis at in in-vivo levels. Moreover, MMP-9 is not the only pathway that it is involved in
regulating metastasis in NSCLC. Therefore, further investigation of tocotrienol involvement in
other metastasis pathways is needed to investigated.
The current research provides substantial evidence that the primary energy source of
NSCLC is glutamine, and that NSCLC exhibits a high rate of glutamine dependency during growth
and development. Furthermore, excess glutamine and essential amino acids in NSCLC are also
reported to upregulate mTOR, a bioenergetics sensor which regulates cell growth, cell survival,
and protein synthesis in NSCLC. In the present work, we employed NMR-based metabolomics
approaches to reveal metabolism regulations of tocotrienol on NSCLC, namely A549 and H1229
cell lines. The metabolomics profiling of NSCLC lysates showed that changes in the glutamine
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related metabolisms are highly affected after treating with δT. Further, δT works by inhibiting
glutamine uptake into proliferating cells through glutamine transporters (LAT-1 and inhibition,
thus resulting in inhibition of cell proliferation and induction of apoptosis via downregulation of
the mTOR pathway. As future directions, investigation of glutamine metabolism using stable
isotopes based flux analysis after treating with/without tocotrienols is needed as it provides a
detailed overview of biochemical pathways of glutamine fate and help in identification of complete
mechanistic pathway. Also, clinical or animal trail may also recommend in performing with δT
supplementation among NSCLC patients to investigate the effect of tocotrienol on glutamine
metabolism at in-vivo levels.
Previously, we reported that δT downregulates the Notch-1 via NF -КB. However, the pure
isomers are presently not available in quantities required for animal or clinical studies. Therefore,
the objective of this study was to investigate the interactions and effects of commercially available
tocotrienols (a mixture of isomers) on the Notch-1 pathway in adenocarcinoma (A549) and
squamous cell carcinoma lung cancer (H520) cell lines. Interestingly, we observed the same effect
with a mixture of tocotrienol isomers directly isolated from the palm oil compared to pure δT.
Briefly, tocotrienol isomers in capsule inhibit cell growth, migration, and tumor cell invasiveness
via down-regulation of Notch 1 and NF -КB while inducing apoptosis. Hence, these commercially
available tocotrienol rich capsule could be an effective therapeutic for lung cancer prevention at
in vivo.
Before going for the in vitro studies, the bioavailability of vitamin E capsules need to be
studied

as

bioavailability

is

always

a

potential

concern

for

all

nutraceuticals.

Although experimental in-vitro evidence has been very promising, oral supplementation of
tocotrienols in animal and human studies has produced inconsistent results [202]. Oral absorption
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of tocotrienols into the circulation is mediated by a carrier transporter system that displays
saturation and down-regulation when exposed to high concentrations of tocotrienols [24, 202]. To
compensate for these limitations in the absorption of tocotrienols, a new delivery system such as
new derivatives and nanoparticle delivery systems could be developed as they significantly
enhance tocotrienol bioavailability. In addition to bioavailability, timing and dosage are also
concerns, and these factors will be different for cell cultures versus animals versus humans. Further
experiments need to be done to investigate whether or not this capsule can show the same results
in animals before it can be taken to a human trial, which is the ultimate goal.
Research on nutraceuticals and their influence on the processes involved in preventing
tumor development, to lower the incidence risk of common cancers, is lacking at the clinical level.
Despite the dearth of clinical data, many cancer patients turn to nutraceuticals from a belief that
they will not cause pain, and may benefit their clinical outcome. Caution is paramount when
considering certain bioactive including tocotrienol, as they may antagonize the activity of
therapeutic agents, or, in some cases, alter their metabolism from efficacious forms. There is a
promise on the horizon, in that there are some molecular targets in common for nutraceuticals
including tocotrienols that have inhibited, at least experimentally in vivo, some aspects of cancer.
Tocotrienols may be generally safe to use during therapy, but this area of research is still immature.
The long-term plan should be to identify novel therapeutic targets of tocotrienols that would allow
innovative utilization of tocotrienols as adjunct to both conventional chemotherapy and radiation
therapy, in order to improve the overall quality of life and survival of patients diagnosed with
cancers.
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ABSTRACT
ANTI-CANCER EFFECTS OF TOCOTRIENOLS IN NSCLC
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Lung cancer is one of the leading causes of death among cancers, with non-small cell lung
cancer (NSCLC) accounting for 80-85% of all lung cancers and a five-year survival rate of 5 % at
stage IIIB. Delta-tocotrienol (δT) including other tocotrienol isomers has been shown to exhibit
anti-tumor activity via inhibition of different signaling pathways in tumors including NSCLC.
Previously we reported that δT reduced cell invasion via inhibition of the Notch-1 and NF-κb
pathway.
Matrix metallopeptidase 9 (MMP9) dependent cell migration and invasion are key
processes in cancer metastasis. Hence, its suppression is a promising strategy for cancer
therapeutics. The objective of specific aim 01 was to investigate the possibility of MMP9 inhibition
as the underlying mechanism behind the anti-metastatic effects of δT on NSCLC cell lines A549
and H1299. Effects of δT on cell migration, invasion, cell adhesion and aggregation capability
were investigated. MMP-9 activity was determined using gel zymography. The various 129
proteins, genes, and miR involved in the Notch-1 and uPA signal transduction pathways have been
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studied for anti-metastatic activity by RT-PCR and western blot. Our findings showed that δT
reduced cell migration, invasion, and adhesion in a dose and time-dependent manner. δT
significantly inhibited MMP-9 activity in gel zymography. Further, δT inhibited Notch-1 mediated
NF-κb and urokinase plasminogen activator (uPA) pathways which lead to the down-regulated
expression of MMP-9 and increased miR 451 expressions. Our data suggests that δT attenuates
tumor aggressiveness, invasion, and metastasis by down-regulation of the MMP-9 gene via Notch1
and uPA pathways
The primary energy source of NSCLC is glutamine, and this cancer exhibits a high rate of
glutamine dependency during its growth and development. Glutamine and essential amino acids
(EAA) in NSCLC are reported to upregulate mTOR, a bioenergetics sensor which regulates cell
growth, cell survival, and protein synthesis. SLC1A5/SLC7A5 transporters that allow glutamine
and EAA to enter the proliferating tumors and send a regulatory signal to mTOR are novel concepts
in cancer cell growth and development. Therefore, inhibiting glutamine uptake via blocking or
downregulating glutamine transporters would be an excellent therapeutic target for NSCLC
treatment. The Specific Aim:2 of this study, was to verify the metabolic dysregulation of glutamine
and its derivatives in NSCLC using cellular 1H-NMR metabolomics approach while investigating
the effect of δT on NSCLC growth and development, glutamine transporters, and mTOR pathway.
Endometabolome of NSCLC was analyzed followed by cellular metabolomics analysis using
SIMCA+ multivariate analyzing software. The results in metabolomics analysis showed
significant inhibition in the uptake of glutamine, its derivatives; glutamate and glutathione, and
some EAA in both cell lines with δT treatment providing their potential use as robust surrogate
biomarkers for δT intervention in NSCLC. To further validation, NMR spectrums were quantified
130 using Chenomx NMR Suite and metabolites were further analyzed using metaboanalyst 3.0
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software. The results in metaboanalyst 3.0 indicated that δT directly impacted on the metabolism
of glutamine and its derivatives where further validating results at previous analysis. Therefore,
expression of glutamine transporters and mTOR pathway proteins were explored, and
dosedependent inhibition of glutamine transporters (SLC7A5 and SLC1A5) and mTOR pathway
proteins (P-mTOR, mTOR, S6K, c-MYC and Bcl-XL) was evident in western blot analysis. Our
findings suggest that δT works by inhibiting glutamine uptake into proliferating cells through
glutamine transporter inhibition thus resulting in inhibition of cell proliferation and induction of
apoptosis via downregulation of the mTOR pathway.
As specific aim, one and two reported that δT shows anti-cancer properties by targeting
different anti-cancer mechanisms. However, the δT are presently not available in quantities
required for animal or clinical studies. Therefore, the objective of specific aim 03 is to investigate
the interactions and effects of commercially available tocotrienols mixture directly isolated from
palm oil (a mixture of isomers) in adenocarcinoma (A549) and squamous cell carcinoma lung
cancer (H520) cell lines. A dose-dependent decrease in all growth was observed in both cancer
cell lines with the addition of tocotrienols by MTS and colonogenic assay. Furthermore, a
significant reduction in cell migration and tumor invasiveness was seen in both cell lines.
Additionally, a significant induction of apoptosis was observed in Annexin V stain in flow
cytometry analysis. Since tocotrienols showed effects against proliferation, apoptosis, migration,
and invasiveness, RT-PCR and western blot analysis were used to explore molecular mechanisms
behind above regulations by testing the expression of Notch-1 and its downstream stream genes.
A dose-dependent decrease in expression was observed in Notch-1, Hes-1, Survivin, MMP-9,
VEGF, and Bcl-XL proteins. Also, we found a mechanism linking the NF-kB pathway and Notch131 1 down-regulation from NF- Кb colorimetric assay. Thus, our data suggests that commercially
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available tocotrienols inhibits cell growth, migration, and tumor cell invasiveness via
downregulation of Notch 1 and NF -КB while inducing apoptosis. Hence, these commercially
available tocotrienol rich capsule could be an effective therapeutic for lung cancer prevention as
same as pure δT. These anticancer effects and mechanisms of δT warrant further investigation of
δT as a potential natural therapeutic approach to prevent NSCLC.
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